{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:08:17Z","timestamp":1794334097080,"version":"4.9.0"},"reference-count":427,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is neuropathologically characterized by the extracellular deposition of the amyloid-\u03b2 peptide (A\u03b2) and the intraneuronal accumulation of abnormal phosphorylated tau (\u03c4)-protein (p-\u03c4). Most frequently, these hallmark lesions are accompanied by other co-pathologies in the brain that may contribute to cognitive impairment, such as vascular lesions, intraneuronal accumulation of phosphorylated transactive-response DNA-binding protein 43 (TDP-43), and\/or \u03b1-synuclein (\u03b1Syn) aggregates. To estimate the extent of these AD and co-pathologies in patients, several biomarkers have been developed. Specific tracers target and visualize A\u03b2 plaques, p-\u03c4 and \u03b1Syn pathology or inflammation by positron emission tomography. In addition to these imaging biomarkers, cerebrospinal fluid, and blood-based biomarker assays reflecting AD-specific or non-specific processes are either already in clinical use or in development. In this review, we will introduce the pathological lesions of the AD brain, the related biomarkers, and discuss to what extent the respective biomarkers estimate the pathology determined at post-mortem histopathological analysis. It became evident that initial stages of A\u03b2 plaque and p-\u03c4 pathology are not detected with the currently available biomarkers. Interestingly, p-\u03c4 pathology precedes A\u03b2 deposition, especially in the beginning of the disease when biomarkers are unable to detect it. Later, A\u03b2 takes the lead and accelerates p-\u03c4 pathology, fitting well with the known evolution of biomarker measures over time. Some co-pathologies still lack clinically established biomarkers today, such as TDP-43 pathology or cortical microinfarcts. In summary, specific biomarkers for AD-related pathologies allow accurate clinical diagnosis of AD based on pathobiological parameters. Although current biomarkers are excellent measures for the respective pathologies, they fail to detect initial stages of the disease for which post-mortem analysis of the brain is still required. Accordingly, neuropathological studies remain essential to understand disease development especially in early stages. Moreover, there is an urgent need for biomarkers reflecting co-pathologies, such as limbic predominant, age-related TDP-43 encephalopathy-related pathology, which is known to modify the disease by interacting with p-\u03c4. Novel biomarker approaches such as extracellular vesicle-based assays and cryptic RNA\/peptides may help to better detect these co-pathologies in the future.<\/jats:p>","DOI":"10.1186\/s13024-025-00819-y","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T06:28:54Z","timestamp":1741933734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-1075","authenticated-orcid":false,"given":"Dietmar Rudolf","family":"Thal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Poesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"819_CR2","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","volume":"261","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084\u20139.","journal-title":"J Biol Chem"},{"key":"819_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"819_CR4","first-page":"116","volume":"4","author":"P Aisen","year":"2017","unstructured":"Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, et al. EU\/US\/CTAD task force: lessons learned from recent and current Alzheimer\u2019s prevention trials. J Prev Alzheimers Dis. 2017;4:116\u201324.","journal-title":"J Prev Alzheimers Dis"},{"key":"819_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"819_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"819_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","volume":"11","author":"DR Thal","year":"2015","unstructured":"Thal DR, Beach TG, Zanette M, Heurling K, Chakrabarty A, Ismail A, Smith AP, Buckley C. [18F]flutemetamol amyloid PET in preclinical and symptomatic Alzheimer\u2019s disease: specific detection of advanced phases of A\u03b2 pathology. Alzheimers Dement. 2015;11:975\u201385.","journal-title":"Alzheimers Dement"},{"key":"819_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"819_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"819_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13550-020-00653-x","volume":"10","author":"MJ Pontecorvo","year":"2020","unstructured":"Pontecorvo MJ, Keene CD, Beach TG, Montine TJ, Arora AK, Devous MD Sr, Navitsky M, Kennedy I, Joshi AD, Lu M, et al. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer\u2019s disease pathology: a clinicopathological study. EJNMMI Res. 2020;10:65.","journal-title":"EJNMMI Res"},{"key":"819_CR11","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/brain\/awv050","volume":"138","author":"ME Murray","year":"2015","unstructured":"Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer\u2019s disease spectrum. Brain. 2015;138:1370\u201381.","journal-title":"Brain"},{"key":"819_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131\u201344.","journal-title":"Nat Rev Neurol"},{"key":"819_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","volume":"47","author":"M Sjogren","year":"2001","unstructured":"Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21\u201393 years of age: establishment of reference values. Clin Chem. 2001;47:1776\u201381.","journal-title":"Clin Chem"},{"key":"819_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"819_CR15","first-page":"1797","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma M, Ashton NJ, Shekari M, Salvado G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"key":"819_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"819_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"819_CR18","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, Kivipelto M, Jessen F, Hanseeuw B, Boada M, et al. Alzheimer disease as a clinical-biological construct-an International Working Group recommendation. JAMA Neurol. 2024;81:1304\u201311.","journal-title":"JAMA Neurol"},{"key":"819_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/awaa438","volume":"144","author":"JL Robinson","year":"2021","unstructured":"Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, Loh N, Porras-Paniagua M, Nirschl JJ, Wolk D, et al. The development and convergence of co-pathologies in Alzheimer\u2019s disease. Brain. 2021;144:953\u201362.","journal-title":"Brain"},{"key":"819_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00401-016-1537-1","volume":"131","author":"KA Josephs","year":"2016","unstructured":"Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW. Updated TDP-43 in Alzheimer\u2019s disease staging scheme. Acta Neuropathol. 2016;131:571\u201385.","journal-title":"Acta Neuropathol"},{"key":"819_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ana.21154","volume":"61","author":"C Amador-Ortiz","year":"2007","unstructured":"Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer\u2019s disease. Ann Neurol. 2007;61:435\u201345.","journal-title":"Ann Neurol"},{"key":"819_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00401-022-02444-1","volume":"144","author":"PT Nelson","year":"2022","unstructured":"Nelson PT, Brayne C, Flanagan ME, Abner EL, Agrawal S, Attems J, Castellani RJ, Corrada MM, Cykowski MD, Di J, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer\u2019s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022;144:27\u201344.","journal-title":"Acta Neuropathol"},{"key":"819_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/brain\/awab027","volume":"144","author":"SO Tome","year":"2021","unstructured":"Tome SO, Thal DR. Co-pathologies in Alzheimer\u2019s disease: just multiple pathologies or partners in crime? Brain. 2021;144:706\u20138.","journal-title":"Brain"},{"key":"819_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/NEN.0b013e31817713b5","volume":"67","author":"K Uryu","year":"2008","unstructured":"Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67:555\u201364.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00401-015-1526-9","volume":"131","author":"JB Toledo","year":"2016","unstructured":"Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, et al. Pathological alpha-synuclein distribution in subjects with coincident Alzheimer\u2019s and Lewy body pathology. Acta Neuropathol. 2016;131:393\u2013409.","journal-title":"Acta Neuropathol"},{"key":"819_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","volume":"115","author":"KA Jellinger","year":"2008","unstructured":"Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115:427\u201336.","journal-title":"Acta Neuropathol"},{"key":"819_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00401-002-0634-5","volume":"105","author":"KA Jellinger","year":"2003","unstructured":"Jellinger KA, Attems J. Incidence of cerebrovascular lesions in Alzheimer\u2019s disease: a postmortem study. Acta Neuropathol. 2003;105:14\u20137.","journal-title":"Acta Neuropathol"},{"key":"819_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.exger.2012.05.023","volume":"47","author":"DR Thal","year":"2012","unstructured":"Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol. 2012;47:816\u201324.","journal-title":"Exp Gerontol"},{"key":"819_CR29","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","volume":"42","author":"PB Gorelick","year":"2011","unstructured":"Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2011;42:2672\u2013713.","journal-title":"Stroke"},{"key":"819_CR30","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/brain\/awt188","volume":"136","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer\u2019s Coordinating Centre. Brain. 2013;136:2697\u2013706.","journal-title":"Brain"},{"key":"819_CR31","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde. Allg Zschr Psych. 1907;64:146\u20138.","journal-title":"Allg Zschr Psych"},{"key":"819_CR32","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","volume":"83","author":"I Grundke-Iqbal","year":"1986","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"819_CR33","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1021\/bi00069a001","volume":"32","author":"JT Jarrett","year":"1993","unstructured":"Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer\u2019s disease. Biochemistry. 1993;32:4693\u20137.","journal-title":"Biochemistry"},{"key":"819_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13:45\u201353.","journal-title":"Neuron"},{"key":"819_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885\u201390.","journal-title":"Biochem Biophys Res Commun"},{"key":"819_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0006-8993(89)91396-6","volume":"477","author":"C Bancher","year":"1989","unstructured":"Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski HM. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer\u2019s disease. Brain Res. 1989;477:90\u20139.","journal-title":"Brain Res"},{"key":"819_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00401-020-02251-6","volume":"141","author":"L Aragao Gomes","year":"2021","unstructured":"Aragao Gomes L, Uytterhoeven V, Lopez-Sanmartin D, Tome SO, Tousseyn T, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Verstreken P, Thal DR. Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. Acta Neuropathol. 2021;141:173\u201392.","journal-title":"Acta Neuropathol"},{"key":"819_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0306-4522(95)90397-P","volume":"64","author":"TG Ohm","year":"1995","unstructured":"Ohm TG, Muller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer\u2019s disease-related neurofibrillary changes. Neuroscience. 1995;64:209\u201317.","journal-title":"Neuroscience"},{"key":"819_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1365-2990.2011.01244.x","volume":"38","author":"J Attems","year":"2012","unstructured":"Attems J, Thomas A, Jellinger K. Correlations between cortical and subcortical tau pathology. Neuropathol Appl Neurobiol. 2012;38:582\u201390.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"819_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1046\/j.0305-1846.2000.00291.x","volume":"26","author":"U Rub","year":"2000","unstructured":"Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. The evolution of Alzheimer\u2019s disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol. 2000;26:553\u201367.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"819_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s004019900178","volume":"100","author":"I Sassin","year":"2000","unstructured":"Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E, Braak H. Evolution of Alzheimer\u2019s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol (Berl). 2000;100:259\u201369.","journal-title":"Acta Neuropathol (Berl)"},{"key":"819_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"819_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"819_CR45","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/brain\/aww023","volume":"139","author":"AJ Schwarz","year":"2016","unstructured":"Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, Mintun MS. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539\u201350.","journal-title":"Brain"},{"key":"819_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.brainresbull.2022.10.006","volume":"190","author":"DR Thal","year":"2022","unstructured":"Thal DR, Tome SO. The central role of tau in Alzheimer\u2019s disease: from neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204\u201317.","journal-title":"Brain Res Bull"},{"key":"819_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00005072-199704000-00001","volume":"56","author":"DW Dickson","year":"1997","unstructured":"Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997;56:321\u201339.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR48","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/00005072-199503000-00014","volume":"54","author":"WS Griffin","year":"1995","unstructured":"Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer\u2019s disease: significance in plaque evolution. J Neuropathol Exp Neurol. 1995;54:276\u201381.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/jnen\/59.8.733","volume":"59","author":"DR Thal","year":"2000","unstructured":"Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 2000;59:733\u201348.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR50","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/00005072-199807000-00004","volume":"57","author":"HM Wisniewski","year":"1998","unstructured":"Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J. Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol. 1998;57:674\u201383.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR51","first-page":"1","volume-title":"Progress in neuropathology 2","author":"HM Wisniewski","year":"1973","unstructured":"Wisniewski HM, Terry RD. Reexamination of the pathogenesis of the senile plaque. In: Zimmerman HM, editor. Progress in neuropathology 2. New York: Grane & Stratton; 1973. p. 1\u201326."},{"key":"819_CR52","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/00005072-199902000-00010","volume":"58","author":"DR Thal","year":"1999","unstructured":"Thal DR, Sassin I, Schultz C, Haass C, Braak E, Braak H. Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta. J Neuropathol Exp Neurol. 1999;58:210\u20136.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR53","doi-asserted-by":"publisher","first-page":"re1","DOI":"10.1126\/sageke.2006.6.re1","volume":"2006","author":"DR Thal","year":"2006","unstructured":"Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006;2006:re1.","journal-title":"Sci Aging Knowledge Environ"},{"key":"819_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology. 1991;41:479\u201386.","journal-title":"Neurology"},{"key":"819_CR55","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"819_CR56","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00401-018-1897-9","volume":"136","author":"DR Thal","year":"2018","unstructured":"Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, Ismail A, Farrar G, Buckley C, Smith APL. Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid beta-protein deposition. Acta Neuropathol. 2018;136:557\u201367.","journal-title":"Acta Neuropathol"},{"issue":"Pt 3","key":"819_CR57","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/brain\/123.3.484","volume":"123","author":"CJ Galton","year":"2000","unstructured":"Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer\u2019s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123(Pt 3):484\u201398.","journal-title":"Brain"},{"key":"819_CR58","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785\u201396.","journal-title":"Lancet Neurol"},{"key":"819_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ana.410420121","volume":"42","author":"R Crook","year":"1997","unstructured":"Crook R, Ellis R, Shanks M, Thal LJ, Perez-Tur J, Baker M, Hutton M, Haltia T, Hardy J, Galasko D. Early-onset Alzheimer\u2019s disease with a presenilin-1 mutation at the site corresponding to the Volga German presenilin-2 mutation. Ann Neurol. 1997;42:124\u20138.","journal-title":"Ann Neurol"},{"key":"819_CR60","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm0498-452","volume":"4","author":"R Crook","year":"1998","unstructured":"Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, et al. A variant of Alzheimer\u2019s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:452\u20135.","journal-title":"Nat Med"},{"key":"819_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.1925564","volume":"254","author":"J Murrell","year":"1991","unstructured":"Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer\u2019s disease. Science. 1991;254:97\u20139.","journal-title":"Science"},{"key":"819_CR62","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ana.410420406","volume":"42","author":"LA Reed","year":"1997","unstructured":"Reed LA, Grabowski TJ, Schmidt ML, Morris JC, Goate A, Solodkin A, Van Hoesen GW, Schelper RL, Talbot CJ, Wragg MA, Trojanowski JQ. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol. 1997;42:564\u201372.","journal-title":"Ann Neurol"},{"key":"819_CR63","doi-asserted-by":"publisher","unstructured":"Daniels AJ, McDade E, Llibre-Guerra JJ, Xiong C, Perrin RJ, Ibanez L, Supnet-Bell C, Cruchaga C, Goate A, Renton AE, et al. 15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.08.08.24311689.","DOI":"10.1101\/2024.08.08.24311689"},{"key":"819_CR64","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jnen\/nlv028","volume":"75","author":"JM Ringman","year":"2016","unstructured":"Ringman JM, Monsell S, Ng DW, Zhou Y, Nguyen A, Coppola G, Van Berlo V, Mendez MF, Tung S, Weintraub S, et al. Neuropathology of autosomal dominant Alzheimer disease in the national Alzheimer coordinating center database. J Neuropathol Exp Neurol. 2016;75:284\u201390.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR65","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00401-020-02198-8","volume":"140","author":"BDC Boon","year":"2020","unstructured":"Boon BDC, Bulk M, Jonker AJ, Morrema THJ, van den Berg E, Popovic M, Walter J, Kumar S, van der Lee SJ, Holstege H, et al. The coarse-grained plaque: a divergent Abeta plaque-type in early-onset Alzheimer\u2019s disease. Acta Neuropathol. 2020;140:811\u201330.","journal-title":"Acta Neuropathol"},{"key":"819_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","volume":"3","author":"CA Lemere","year":"1996","unstructured":"Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3:16\u201332.","journal-title":"Neurobiol Dis"},{"key":"819_CR67","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20:930\u201342.","journal-title":"Lancet Neurol"},{"key":"819_CR68","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.neurobiolaging.2015.05.016","volume":"36","author":"DM Wilcock","year":"2015","unstructured":"Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E. Down syndrome individuals with Alzheimer\u2019s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer\u2019s disease. Neurobiol Aging. 2015;36:2468\u201374.","journal-title":"Neurobiol Aging"},{"key":"819_CR69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ana.410240110","volume":"24","author":"CL Joachim","year":"1988","unstructured":"Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer\u2019s disease: autopsy results in 150 cases. Ann Neurol. 1988;24:50\u20136.","journal-title":"Ann Neurol"},{"key":"819_CR70","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/01.STR.14.6.924","volume":"14","author":"HV Vinters","year":"1983","unstructured":"Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke. 1983;14:924\u20138.","journal-title":"Stroke"},{"key":"819_CR71","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1212\/WNL.25.2.120","volume":"25","author":"TI Mandybur","year":"1975","unstructured":"Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer\u2019s disease. Neurology. 1975;25:120\u20136.","journal-title":"Neurology"},{"key":"819_CR72","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/j.1582-4934.2008.00411.x","volume":"12","author":"DR Thal","year":"2008","unstructured":"Thal DR, Griffin WS, Braak H. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer\u2019s disease. J Cell Mol Med. 2008;12:1848\u201362.","journal-title":"J Cell Mol Med"},{"key":"819_CR73","doi-asserted-by":"publisher","first-page":"e93621","DOI":"10.1172\/jci.insight.93621","volume":"2","author":"Y Koronyo","year":"2017","unstructured":"Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight. 2017;2:e93621.","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"819_CR74","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.neuroimage.2010.06.020","volume":"54","author":"M Koronyo-Hamaoui","year":"2011","unstructured":"Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL. Identification of amyloid plaques in retinas from Alzheimer\u2019s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54(Suppl 1):S204-217.","journal-title":"Neuroimage"},{"key":"819_CR75","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1002\/alz.13086","volume":"19","author":"H Shi","year":"2023","unstructured":"Shi H, Koronyo Y, Fuchs DT, Sheyn J, Jallow O, Mandalia K, Graham SL, Gupta VK, Mirzaei M, Kramerov AA, et al. Retinal arterial Abeta(40) deposition is linked with tight junction loss and cerebral amyloid angiopathy in MCI and AD patients. Alzheimers Dement. 2023;19:5185\u201397.","journal-title":"Alzheimers Dement"},{"key":"819_CR76","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40478-018-0650-x","volume":"6","author":"J den Haan","year":"2018","unstructured":"den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, Bergen AAB, Bouwman FH, Hoozemans JJ. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer\u2019s disease retinas. Acta Neuropathol Commun. 2018;6:147.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR77","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00401-022-02525-1","volume":"145","author":"FJ Hart de Ruyter","year":"2023","unstructured":"Hart de Ruyter FJ, Morrema THJ, den Haan J, Netherlands Brain B, Twisk JWR, de Boer JF, Scheltens P, Boon BDC, Thal DR, Rozemuller AJ, et al. Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer\u2019s disease and primary tauopathies. Acta Neuropathol. 2023;145:197\u2013218.","journal-title":"Acta Neuropathol"},{"key":"819_CR78","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/alz.13424","volume":"20","author":"G Walkiewicz","year":"2024","unstructured":"Walkiewicz G, Ronisz A, Van Ginderdeuren R, Lemmens S, Bouwman FH, Hoozemans JJM, Morrema THJ, Rozemuller AJ, Hart de Ruyter FJ, De Groef L, et al. Primary retinal tauopathy: a tauopathy with a distinct molecular pattern. Alzheimers Dement. 2024;20:330\u201340.","journal-title":"Alzheimers Dement"},{"key":"819_CR79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3129\/i07-185","volume":"43","author":"N Gupta","year":"2008","unstructured":"Gupta N, Fong J, Ang LC, Yucel YH. Retinal tau pathology in human glaucomas. Can J Ophthalmol. 2008;43:53\u201360.","journal-title":"Can J Ophthalmol"},{"key":"819_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00401-024-02769-z","volume":"148","author":"FJ Hart de Ruyter","year":"2024","unstructured":"Hart de Ruyter FJ, Evers M, Morrema THJ, Dijkstra AA, den Haan J, Twisk JWR, de Boer JF, Scheltens P, Bouwman FH, Verbraak FD, et al. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases. Acta Neuropathol. 2024;148:24.","journal-title":"Acta Neuropathol"},{"key":"819_CR81","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s40478-024-01907-8","volume":"12","author":"G Walkiewicz","year":"2024","unstructured":"Walkiewicz G, Ronisz A, Ospitalieri S, Tsaka G, Tom\u00e9 SO, Vandenberghe R, von Arnim CAF, Rousseau F, Schymkowitz J, De Groef L, Thal DR. pTau pathology in the retina of TAU58 mice: association with ganglion cell degeneration and implications on seeding and propagation of pTau from human brain lysates. Acta Neuropathol Commun. 2024;12:194.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR82","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.2.47","volume":"9","author":"Y Qiu","year":"2020","unstructured":"Qiu Y, Jin T, Mason E, Campbell MCW. Predicting thioflavin fluorescence of retinal amyloid deposits associated with Alzheimer\u2019s disease from their polarimetric properties. Transl Vis Sci Technol. 2020;9: 47.","journal-title":"Transl Vis Sci Technol"},{"key":"819_CR83","first-page":"267","volume-title":"Histologie und histopathologische Arbeiten \u00fcber die Gro\u00dfhirnrinde","author":"T Simchowicz","year":"1911","unstructured":"Simchowicz T. Histopathologische Studien \u00fcber die senile Demenz. In: Nissl F, Alzheimer A, editors. Histologie und histopathologische Arbeiten \u00fcber die Gro\u00dfhirnrinde, vol. 4. Jena: Fischer; 1911. p. 267\u2013444."},{"key":"819_CR84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/BF00692056","volume":"37","author":"MJ Ball","year":"1977","unstructured":"Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol. 1977;37:111\u20138.","journal-title":"Acta Neuropathol"},{"key":"819_CR85","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00401-011-0871-6","volume":"122","author":"DR Thal","year":"2011","unstructured":"Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJ, Rozemuller AJ, Braak H, Knippschild U. Stages of granulovacuolar degeneration: their relation to Alzheimer\u2019s disease and chronic stress response. Acta Neuropathol. 2011;122:577\u201389.","journal-title":"Acta Neuropathol"},{"key":"819_CR86","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Inflammation and Alzheimer\u2019s disease. Neurobiol Aging. 2000;21:383\u2013421.","journal-title":"Neurobiol Aging"},{"key":"819_CR87","doi-asserted-by":"publisher","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","volume":"86","author":"WS Griffin","year":"1989","unstructured":"Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86:7611\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"819_CR88","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1017\/S0317167100029863","volume":"16","author":"PL McGeer","year":"1989","unstructured":"McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer\u2019s disease. Can J Neurol Sci. 1989;16:516\u201327.","journal-title":"Can J Neurol Sci"},{"key":"819_CR89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"819_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01104-7","author":"MT Heneka","year":"2024","unstructured":"Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, Brosseron F, Teunissen C, Zetterberg H, Jacobs AH, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2024. https:\/\/doi.org\/10.1038\/s41577-024-01104-7.","journal-title":"Nat Rev Immunol"},{"key":"819_CR91","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5858\/2004-128-32-CID","volume":"128","author":"C Fu","year":"2004","unstructured":"Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004;128:32\u20138.","journal-title":"Arch Pathol Lab Med"},{"key":"819_CR92","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/jnen\/59.11.931","volume":"59","author":"HV Vinters","year":"2000","unstructured":"Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, Chui HC. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol. 2000;59:931\u201345.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR93","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/ana.22520","volume":"70","author":"LJ Launer","year":"2011","unstructured":"Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia aging study autopsy study. Ann Neurol. 2011;70:774\u201380.","journal-title":"Ann Neurol"},{"key":"819_CR94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2002.tb04794.x","volume":"977","author":"L White","year":"2002","unstructured":"White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, Masaki K, Launer L, Markesbery WR. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann N Y Acad Sci. 2002;977:9\u201323.","journal-title":"Ann N Y Acad Sci"},{"key":"819_CR95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00401-010-0652-7","volume":"119","author":"LT Grinberg","year":"2010","unstructured":"Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta Neuropathol. 2010;119:277\u201390.","journal-title":"Acta Neuropathol"},{"key":"819_CR96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00005072-194901000-00003","volume":"8","author":"C Fazio","year":"1949","unstructured":"Fazio C. Red softening of the brain. J Neuropathol Exp Neurol. 1949;8:43\u201360.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR97","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1212\/WNL.15.8.774","volume":"15","author":"CM Fisher","year":"1965","unstructured":"Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology. 1965;15:774\u201384.","journal-title":"Neurology"},{"key":"819_CR98","unstructured":"Liberato B, Chong JY, Sacco RL. Focal brain ischemia. Clinical features, epidemiology, risk factors and outcome. In: Kalimo H, editor. Cerebrovascular diseases. Basel: ISN Neuropath Press; 2005. p. 176\u2013185. Pathology & Genetics."},{"key":"819_CR99","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1750-3639.2002.tb00450.x","volume":"12","author":"GA Lammie","year":"2002","unstructured":"Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol. 2002;12:358\u201370.","journal-title":"Brain Pathol"},{"key":"819_CR100","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00005072-198601000-00007","volume":"45","author":"TI Mandybur","year":"1986","unstructured":"Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol. 1986;45:79\u201390.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR101","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1750-3639.2009.00322.x","volume":"20","author":"V Soontornniyomkij","year":"2009","unstructured":"Soontornniyomkij V, Lynch MD, Mermash S, Pomakian J, Badkoobehi H, Clare R, Vinters HV. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol. 2009;20:459\u201367.","journal-title":"Brain Pathol"},{"key":"819_CR102","doi-asserted-by":"publisher","first-page":"14088","DOI":"10.1073\/pnas.96.24.14088","volume":"96","author":"ME Calhoun","year":"1999","unstructured":"Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999;96:14088\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"819_CR103","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00401-010-0707-9","volume":"120","author":"DR Thal","year":"2010","unstructured":"Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer\u2019s disease. Acta Neuropathol. 2010;120:169\u201383.","journal-title":"Acta Neuropathol"},{"key":"819_CR104","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, Blennow K, Cummings J, van Duijn C, Nilsson PM, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23:53\u201366.","journal-title":"Nat Rev Neurosci"},{"key":"819_CR105","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jnen\/61.3.282","volume":"61","author":"DR Thal","year":"2002","unstructured":"Thal DR, Ghebremedhin E, R\u00fcb U, Yamaguchi H, Del Tredici K, Braak H. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2002;61:282\u201393.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR106","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.neurobiolaging.2008.01.017","volume":"30","author":"DR Thal","year":"2009","unstructured":"Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging. 2009;30:1936\u201348.","journal-title":"Neurobiol Aging"},{"key":"819_CR107","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00401-018-1834-y","volume":"135","author":"M Hecht","year":"2018","unstructured":"Hecht M, Kramer LM, von Arnim CAF, Otto M, Thal DR. Capillary cerebral amyloid angiopathy in Alzheimer\u2019s disease: association with allocortical\/hippocampal microinfarcts and cognitive decline. Acta Neuropathol. 2018;135:681\u201394.","journal-title":"Acta Neuropathol"},{"key":"819_CR108","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327.","journal-title":"Brain"},{"key":"819_CR109","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-021-02295-2","volume":"141","author":"SO Tome","year":"2021","unstructured":"Tome SO, Gomes LA, Li X, Vandenberghe R, Tousseyn T, Thal DR. TDP-43 interacts with pathological tau protein in Alzheimer\u2019s disease. Acta Neuropathol. 2021;141:795\u20139.","journal-title":"Acta Neuropathol"},{"key":"819_CR110","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00401-013-1211-9","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, Petersen RC, Dickson DW. Staging TDP-43 pathology in Alzheimer\u2019s disease. Acta Neuropathol. 2014;127:441\u201350.","journal-title":"Acta Neuropathol"},{"key":"819_CR111","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1474-4422(17)30284-3","volume":"16","author":"KA Josephs","year":"2017","unstructured":"Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, Liesinger AM, Senjem ML, Spychalla AJ, Knopman DS, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer\u2019s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16:917\u201324.","journal-title":"Lancet Neurol"},{"key":"819_CR112","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia. Brain. 2016;139:2983\u201393.","journal-title":"Brain"},{"key":"819_CR113","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00401-009-0594-0","volume":"118","author":"PG Foulds","year":"2009","unstructured":"Foulds PG, Davidson Y, Mishra M, Hobson DJ, Humphreys KM, Taylor M, Johnson N, Weintraub S, Akiyama H, Arai T, et al. Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol. 2009;118:647\u201358.","journal-title":"Acta Neuropathol"},{"key":"819_CR114","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/bpa.12424","volume":"27","author":"KE McAleese","year":"2017","unstructured":"McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer\u2019s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27:472\u20139.","journal-title":"Brain Pathol"},{"key":"819_CR115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-022-02524-2","volume":"145","author":"PT Nelson","year":"2023","unstructured":"Nelson PT, Lee EB, Cykowski MD, Alafuzoff I, Arfanakis K, Attems J, Brayne C, Corrada MM, Dugger BN, Flanagan ME, et al. LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 2023;145:159\u201373.","journal-title":"Acta Neuropathol"},{"key":"819_CR116","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00401-023-02623-8","volume":"146","author":"AA Dijkstra","year":"2023","unstructured":"Dijkstra AA, Morrema THJ, Hart de Ruyter FJ, Gami-Patel P, Verbraak FD, de Boer JF, Bouwman FH, Pijnenburg YAL, den Haan J, Rozemuller AJ, Hoozemans JJM. TDP-43 pathology in the retina of patients with frontotemporal lobar degeneration. Acta Neuropathol. 2023;146:767\u201370.","journal-title":"Acta Neuropathol"},{"key":"819_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1110520","volume":"15","author":"N Pediconi","year":"2023","unstructured":"Pediconi N, Gigante Y, Cama S, Pitea M, Mautone L, Ruocco G, Ghirga S, Di Angelantonio S. Retinal fingerprints of ALS in patients: Ganglion cell apoptosis and TDP-43\/p62 misplacement. Front Aging Neurosci. 2023;15: 1110520.","journal-title":"Front Aging Neurosci"},{"key":"819_CR118","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130\u20133.","journal-title":"Science"},{"key":"819_CR119","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0006-8993(00)03082-1","volume":"888","author":"Y Arai","year":"2001","unstructured":"Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer\u2019s disease: morphology and its relationship to tau aggregation. Brain Res. 2001;888:287\u201396.","journal-title":"Brain Res"},{"key":"819_CR120","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton RL. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10:378\u201384.","journal-title":"Brain Pathol"},{"key":"819_CR121","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","volume":"153","author":"CF Lippa","year":"1998","unstructured":"Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O\u2019Connell B, Pollen DA, St George-Hyslop P, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer\u2019s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153:1365\u201370.","journal-title":"Am J Pathol"},{"key":"819_CR122","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/01.jnen.0000225908.90052.07","volume":"65","author":"H Uchikado","year":"2006","unstructured":"Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65:685\u201397.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR123","doi-asserted-by":"publisher","first-page":"e12189","DOI":"10.1002\/dad2.12189","volume":"13","author":"A Chatterjee","year":"2021","unstructured":"Chatterjee A, Hirsch-Reinshagen V, Moussavi SA, Ducharme B, Mackenzie IR, Hsiung GR. Clinico-pathological comparison of patients with autopsy-confirmed Alzheimer\u2019s disease, dementia with Lewy bodies, and mixed pathology. Alzheimers Dement (Amst). 2021;13:e12189.","journal-title":"Alzheimers Dement (Amst)"},{"key":"819_CR124","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neurobiolaging.2017.01.017","volume":"53","author":"WD Brenowitz","year":"2017","unstructured":"Brenowitz WD, Keene CD, Hawes SE, Hubbard RA, Longstreth WT Jr, Woltjer RL, Crane PK, Larson EB, Kukull WA. Alzheimer\u2019s disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging. 2017;53:83\u201392.","journal-title":"Neurobiol Aging"},{"key":"819_CR125","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16:55\u201365.","journal-title":"Lancet Neurol"},{"key":"819_CR126","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","volume":"64","author":"ML Kraybill","year":"2005","unstructured":"Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology. 2005;64:2069\u201373.","journal-title":"Neurology"},{"key":"819_CR127","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"819_CR128","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00401-009-0523-2","volume":"117","author":"I Alafuzoff","year":"2009","unstructured":"Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, et al. Staging\/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117:635\u201352.","journal-title":"Acta Neuropathol"},{"key":"819_CR129","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-020-02255-2","volume":"141","author":"J Attems","year":"2021","unstructured":"Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G, Hortobagyi T, Jellinger K, Kovacs GG, Lee EB, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141:159\u201372.","journal-title":"Acta Neuropathol"},{"key":"819_CR130","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117:613\u201334.","journal-title":"Acta Neuropathol"},{"key":"819_CR131","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1750-3639.2007.00117.x","volume":"18","author":"JB Leverenz","year":"2008","unstructured":"Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008;18:220\u20134.","journal-title":"Brain Pathol"},{"key":"819_CR132","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00702-004-0138-7","volume":"111","author":"KA Jellinger","year":"2004","unstructured":"Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna). 2004;111:1219\u201335.","journal-title":"J Neural Transm (Vienna)"},{"key":"819_CR133","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/emmm.201302475","volume":"5","author":"A Ulusoy","year":"2013","unstructured":"Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA. Caudo-rostral brain spreading of alpha-synuclein through vagal connections. EMBO Mol Med. 2013;5:1119\u201327.","journal-title":"EMBO Mol Med"},{"key":"819_CR134","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"819_CR135","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72:587\u201398.","journal-title":"Ann Neurol"},{"key":"819_CR136","doi-asserted-by":"publisher","first-page":"fcae442","DOI":"10.1093\/braincomms\/fcae442","volume":"6","author":"K Gawor","year":"2024","unstructured":"Gawor K, Tome SO, Vandenberghe R, Van Damme P, Vandenbulcke M, Otto M, von Arnim CAF, Ghebremedhin E, Ronisz A, Ospitalieri S, et al. Amygdala-predominant alpha-synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer\u2019s disease. Brain Commun. 2024;6:fcae442.","journal-title":"Brain Commun"},{"key":"819_CR137","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/brain\/awab099","volume":"144","author":"S Spina","year":"2021","unstructured":"Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, Hepker M, Hwang JH, Miller ZA, Huang EJ, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain. 2021;144:2186\u201398.","journal-title":"Brain"},{"key":"819_CR138","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neulet.2014.04.027","volume":"571","author":"TG Beach","year":"2014","unstructured":"Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N, Arizona Parkinson\u2019s Disease C. Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson\u2019s disease subjects. Neurosci Lett. 2014;571:34\u20138.","journal-title":"Neurosci Lett"},{"key":"819_CR139","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41531-023-00570-5","volume":"9","author":"FJ Hart de Ruyter","year":"2023","unstructured":"Hart de Ruyter FJ, Morrema THJ, den Haan J, Gase G, Twisk JWR, de Boer JF, Scheltens P, Bouwman FH, Verbraak FD, Rozemuller AJM, Hoozemans JJM. alpha-Synuclein pathology in post-mortem retina and optic nerve is specific for alpha-synucleinopathies. NPJ Parkinsons Dis. 2023;9:124.","journal-title":"NPJ Parkinsons Dis"},{"key":"819_CR140","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00401-018-01956-z","volume":"137","author":"L Veys","year":"2019","unstructured":"Veys L, Vandenabeele M, Ortuno-Lizaran I, Baekelandt V, Cuenca N, Moons L, De Groef L. Retinal alpha-synuclein deposits in Parkinson\u2019s disease patients and animal models. Acta Neuropathol. 2019;137:379\u201395.","journal-title":"Acta Neuropathol"},{"key":"819_CR141","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/00005072-197705000-00006","volume":"36","author":"MJ Ball","year":"1977","unstructured":"Ball MJ, Lo P. Granulovacuolar degeneration in the ageing brain and in dementia. J Neuropathol Exp Neurol. 1977;36:474\u201387.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR142","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00005072-196804000-00001","volume":"27","author":"A Hirano","year":"1968","unstructured":"Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM. The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and \u201crod-like\u201d structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. J Neuropathol Exp Neurol. 1968;27:167\u201382.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR143","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00401-016-1562-0","volume":"132","author":"C Kohler","year":"2016","unstructured":"Kohler C. Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology. Acta Neuropathol. 2016;132:339\u201359.","journal-title":"Acta Neuropathol"},{"key":"819_CR144","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2990.2010.01135.x","volume":"37","author":"KE Funk","year":"2011","unstructured":"Funk KE, Mrak RE, Kuret J. Granulovacuolar degeneration bodies of Alzheimer\u2019s disease resemble late-stage autophagic organelles. Neuropathol Appl Neurobiol. 2011;37:295\u2013306.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"819_CR145","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00401-019-02103-y","volume":"139","author":"MJ Koper","year":"2020","unstructured":"Koper MJ, Van Schoor E, Ospitalieri S, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Tousseyn T, Balusu S, De Strooper B, Thal DR. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer\u2019s disease. Acta Neuropathol. 2020;139:463\u201384.","journal-title":"Acta Neuropathol"},{"key":"819_CR146","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s40478-021-01264-w","volume":"9","author":"A Jayaraman","year":"2021","unstructured":"Jayaraman A, Htike TT, James R, Picon C, Reynolds R. TNF-mediated neuroinflammation is linked to neuronal necroptosis in Alzheimer\u2019s disease hippocampus. Acta Neuropathol Commun. 2021;9:159.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR147","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00401-019-02028-6","volume":"138","author":"Y Riku","year":"2019","unstructured":"Riku Y, Duyckaerts C, Boluda S, Plu I, Le Ber I, Millecamps S, Salachas F, Brainbank Neuro CEBNN, Yoshida M, Ando T, et al. Increased prevalence of granulovacuolar degeneration in C9orf72 mutation. Acta Neuropathol. 2019;138:783\u201393.","journal-title":"Acta Neuropathol"},{"key":"819_CR148","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0304-3940(89)90843-4","volume":"107","author":"PL McGeer","year":"1989","unstructured":"McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989;107:341\u20136.","journal-title":"Neurosci Lett"},{"key":"819_CR149","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0304-3940(87)90696-3","volume":"79","author":"PL McGeer","year":"1987","unstructured":"McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195\u2013200.","journal-title":"Neurosci Lett"},{"key":"819_CR150","first-page":"223","volume":"66","author":"S Strauss","year":"1992","unstructured":"Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer\u2019s disease patients. Lab Invest. 1992;66:223\u201330.","journal-title":"Lab Invest"},{"key":"819_CR151","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0197-4580(98)00090-6","volume":"19","author":"DR Thal","year":"1998","unstructured":"Thal DR, Arendt T, Waldmann G, Holzer M, Zedlick D, R\u00fcb U, Schober R. Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer\u2019s disease is different from plaque and cortical microglial pathology. Neurobiol Aging. 1998;19:517\u201325.","journal-title":"Neurobiol Aging"},{"key":"819_CR152","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41593-024-01600-y","volume":"27","author":"R Mancuso","year":"2024","unstructured":"Mancuso R, Fattorelli N, Martinez-Muriana A, Davis E, Wolfs L, Van Den Daele J, Geric I, Premereur J, Polanco P, Bijnens B, et al. Xenografted human microglia display diverse transcriptomic states in response to Alzheimer\u2019s disease-related amyloid-beta pathology. Nat Neurosci. 2024;27:886\u2013900.","journal-title":"Nat Neurosci"},{"key":"819_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109228","volume":"35","author":"Y Hu","year":"2021","unstructured":"Hu Y, Fryatt GL, Ghorbani M, Obst J, Menassa DA, Martin-Estebane M, Muntslag TAO, Olmos-Alonso A, Guerrero-Carrasco M, Thomas D, et al. Replicative senescence dictates the emergence of disease-associated microglia and contributes to Abeta pathology. Cell Rep. 2021;35: 109228.","journal-title":"Cell Rep"},{"key":"819_CR154","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276-1290 e1217.","journal-title":"Cell"},{"key":"819_CR155","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493:674\u20138.","journal-title":"Nature"},{"key":"819_CR156","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669\u201373.","journal-title":"Nature"},{"key":"819_CR157","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00401-024-02790-2","volume":"148","author":"P Botella Lucena","year":"2024","unstructured":"Botella Lucena P, Heneka MT. Inflammatory aspects of Alzheimer\u2019s disease. Acta Neuropathol. 2024;148:31.","journal-title":"Acta Neuropathol"},{"key":"819_CR158","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","volume":"29","author":"D Tang","year":"2019","unstructured":"Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347\u201364.","journal-title":"Cell Res"},{"key":"819_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030161","volume":"3","author":"T Bergsbaken","year":"2007","unstructured":"Bergsbaken T, Cookson BT. Macrophage activation redirects yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. PLoS Pathog. 2007;3: e161.","journal-title":"PLoS Pathog"},{"key":"819_CR160","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00401-022-02528-y","volume":"145","author":"S Moonen","year":"2023","unstructured":"Moonen S, Koper MJ, Van Schoor E, Schaeverbeke JM, Vandenberghe R, von Arnim CAF, Tousseyn T, De Strooper B, Thal DR. Pyroptosis in Alzheimer\u2019s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 2023;145:175\u201395.","journal-title":"Acta Neuropathol"},{"key":"819_CR161","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00401-024-02722-0","volume":"147","author":"DR Thal","year":"2024","unstructured":"Thal DR, Gawor K, Moonen S. Regulated cell death and its role in Alzheimer\u2019s disease and amyotrophic lateral sclerosis. Acta Neuropathol. 2024;147:69.","journal-title":"Acta Neuropathol"},{"key":"819_CR162","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40478-022-01432-6","volume":"10","author":"MJ Koper","year":"2022","unstructured":"Koper MJ, Tome SO, Gawor K, Belet A, Van Schoor E, Schaeverbeke J, Vandenberghe R, Vandenbulcke M, Ghebremedhin E, Otto M, et al. LATE-NC aggravates GVD-mediated necroptosis in Alzheimer\u2019s disease. Acta Neuropathol Commun. 2022;10:128.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR163","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00401-013-1139-0","volume":"126","author":"H Braak","year":"2013","unstructured":"Braak H, Zetterberg H, Del Tredici K, Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013;126:631\u201341.","journal-title":"Acta Neuropathol"},{"key":"819_CR164","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00401-015-1390-7","volume":"129","author":"C Duyckaerts","year":"2015","unstructured":"Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129:749\u201356.","journal-title":"Acta Neuropathol"},{"key":"819_CR165","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0197-4580(91)90006-6","volume":"12","author":"JL Price","year":"1991","unstructured":"Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer\u2019s disease. Neurobiol Aging. 1991;12:295\u2013312.","journal-title":"Neurobiol Aging"},{"key":"819_CR166","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-017-1709-7","volume":"134","author":"TL Spires-Jones","year":"2017","unstructured":"Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187\u2013205.","journal-title":"Acta Neuropathol"},{"key":"819_CR167","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.1062097","volume":"293","author":"J Gotz","year":"2001","unstructured":"Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491\u20135.","journal-title":"Science"},{"key":"819_CR168","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1126\/science.1058189","volume":"293","author":"J Lewis","year":"2001","unstructured":"Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487\u201391.","journal-title":"Science"},{"key":"819_CR169","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00401-019-02053-5","volume":"138","author":"LA Gomes","year":"2019","unstructured":"Gomes LA, Hipp SA, Rijal Upadhaya A, Balakrishnan K, Ospitalieri S, Koper MJ, Largo-Barrientos P, Uytterhoeven V, Reichwald J, Rabe S, et al. Abeta-induced acceleration of Alzheimer-related tau-pathology spreading and its association with prion protein. Acta Neuropathol. 2019;138:913\u201341.","journal-title":"Acta Neuropathol"},{"key":"819_CR170","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00401-024-02839-2","volume":"149","author":"S Kadamangudi","year":"2024","unstructured":"Kadamangudi S, Marcatti M, Zhang WR, Fracassi A, Kayed R, Limon A, Taglialatela G. Amyloid-beta oligomers increase the binding and internalization of tau oligomers in human synapses. Acta Neuropathol. 2024;149:2.","journal-title":"Acta Neuropathol"},{"key":"819_CR171","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00401-019-02114-9","volume":"139","author":"GT Corbett","year":"2020","unstructured":"Corbett GT, Wang Z, Hong W, Colom-Cadena M, Rose J, Liao M, Asfaw A, Hall TC, Ding L, DeSousa A, et al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 2020;139:503\u201326.","journal-title":"Acta Neuropathol"},{"key":"819_CR172","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00401-019-02046-4","volume":"138","author":"VI Wiersma","year":"2019","unstructured":"Wiersma VI, van Ziel AM, Vazquez-Sanchez S, Nolle A, Berenjeno-Correa E, Bonaterra-Pastra A, Clavaguera F, Tolnay M, Musters RJP, van Weering JRT, et al. Granulovacuolar degeneration bodies are neuron-selective lysosomal structures induced by intracellular tau pathology. Acta Neuropathol. 2019;138:943\u201370.","journal-title":"Acta Neuropathol"},{"key":"819_CR173","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nbd.2014.07.006","volume":"71","author":"C Kohler","year":"2014","unstructured":"Kohler C, Dinekov M, Gotz J. Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Abeta amyloidosis. Neurobiol Dis. 2014;71:169\u201379.","journal-title":"Neurobiol Dis"},{"key":"819_CR174","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1126\/science.abp9556","volume":"381","author":"S Balusu","year":"2023","unstructured":"Balusu S, Horre K, Thrupp N, Craessaerts K, Snellinx A, Serneels L, T\u2019Syen D, Chrysidou I, Arranz AM, Sierksma A, et al. MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer\u2019s disease. Science. 2023;381:1176\u201382.","journal-title":"Science"},{"key":"819_CR175","doi-asserted-by":"publisher","first-page":"eadf5128","DOI":"10.1126\/scitranslmed.adf5128","volume":"16","author":"MJ Koper","year":"2024","unstructured":"Koper MJ, Moonen S, Ronisz A, Ospitalieri S, Callaerts-Vegh Z, T\u2019Syen D, Rabe S, Staufenbiel M, De Strooper B, Balusu S, Thal DR. Inhibition of an Alzheimer\u2019s disease-associated form of necroptosis rescues neuronal death in mouse models. Sci Transl Med. 2024;16:eadf5128.","journal-title":"Sci Transl Med"},{"key":"819_CR176","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13024-023-00653-0","volume":"18","author":"SO Tome","year":"2023","unstructured":"Tome SO, Tsaka G, Ronisz A, Ospitalieri S, Gawor K, Gomes LA, Otto M, von Arnim CAF, Van Damme P, Van Den Bosch L, et al. TDP-43 pathology is associated with increased tau burdens and seeding. Mol Neurodegener. 2023;18:71.","journal-title":"Mol Neurodegener"},{"key":"819_CR177","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s11357-021-00407-0","volume":"43","author":"CS Latimer","year":"2021","unstructured":"Latimer CS, Liachko NF. Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer\u2019s disease. Geroscience. 2021;43:1627\u201334.","journal-title":"Geroscience"},{"key":"819_CR178","doi-asserted-by":"publisher","first-page":"dmm049323","DOI":"10.1242\/dmm.049323","volume":"15","author":"CS Latimer","year":"2022","unstructured":"Latimer CS, Stair JG, Hincks JC, Currey HN, Bird TD, Keene CD, Kraemer BC, Liachko NF. TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic Caenorhabditis elegans. Dis Model Mech. 2022;15:dmm049323.","journal-title":"Dis Model Mech"},{"key":"819_CR179","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/brain\/aww229","volume":"139","author":"SJ van Veluw","year":"2016","unstructured":"van Veluw SJ, Charidimou A, van der Kouwe AJ, Lauer A, Reijmer YD, Costantino I, Gurol ME, Biessels GJ, Frosch MP, Viswanathan A, Greenberg SM. Microbleed and microinfarct detection in amyloid angiopathy: a high-resolution MRI-histopathology study. Brain. 2016;139:3151\u201362.","journal-title":"Brain"},{"key":"819_CR180","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(09)70013-4","volume":"8","author":"SM Greenberg","year":"2009","unstructured":"Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165\u201374.","journal-title":"Lancet Neurol"},{"key":"819_CR181","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Roman","year":"1993","unstructured":"Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250\u201360.","journal-title":"Neurology"},{"key":"819_CR182","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.STR.0000237236.88823.47","volume":"37","author":"V Hachinski","year":"2006","unstructured":"Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, et al. National Institute of Neurological Disorders and Stroke-Canadian stroke network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220\u201341.","journal-title":"Stroke"},{"key":"819_CR183","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41380-024-02656-9","volume":"30","author":"F Chauveau","year":"2025","unstructured":"Chauveau F, Winkeler A, Chalon S, Boutin H, Becker G. PET imaging of neuroinflammation: any credible alternatives to TSPO yet? Mol Psychiatry. 2025;30:213\u201328.","journal-title":"Mol Psychiatry"},{"key":"819_CR184","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbi.2023.07.023","volume":"113","author":"LJ De Picker","year":"2023","unstructured":"De Picker LJ, Morrens M, Branchi I, Haarman BCM, Terada T, Kang MS, Boche D, Tremblay ME, Leroy C, Bottlaender M, Ottoy J. TSPO PET brain inflammation imaging: a transdiagnostic systematic review and meta-analysis of 156 case-control studies. Brain Behav Immun. 2023;113:415\u201331.","journal-title":"Brain Behav Immun"},{"key":"819_CR185","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2967\/jnumed.119.231985","volume":"61","author":"D Van Weehaeghe","year":"2020","unstructured":"Van Weehaeghe D, Van Schoor E, De Vocht J, Koole M, Attili B, Celen S, Declercq L, Thal DR, Van Damme P, Bormans G, Van Laere K. TSPO versus P2X7 as a target for neuroinflammation: an in vitro and in vivo study. J Nucl Med. 2020;61:604\u20137.","journal-title":"J Nucl Med"},{"key":"819_CR186","doi-asserted-by":"publisher","first-page":"fcae162","DOI":"10.1093\/braincomms\/fcae162","volume":"6","author":"S De Meyer","year":"2024","unstructured":"De Meyer S, Schaeverbeke JM, Luckett ES, Reinartz M, Blujdea ER, Cleynen I, Dupont P, Van Laere K, Vanbrabant J, Stoops E, et al. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET. Brain Commun. 2024;6:fcae162.","journal-title":"Brain Commun"},{"key":"819_CR187","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5414\/NP301564","volume":"42","author":"DR Thal","year":"2023","unstructured":"Thal DR, Gawor K. Cerebral amyloid angiopathy: neuropathological diagnosis, link to Alzheimer\u2019s disease and impact on clinics. Clin Neuropathol. 2023;42:176\u201389.","journal-title":"Clin Neuropathol"},{"key":"819_CR188","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","volume":"21","author":"A Charidimou","year":"2022","unstructured":"Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, Banerjee G, Barbato C, Bonneville F, Brandner S, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21:714\u201325.","journal-title":"Lancet Neurol"},{"key":"819_CR189","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/alz.12511","volume":"18","author":"CE Gleason","year":"2022","unstructured":"Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, Lambrou NH, Wyman MF, Ketchum FB, Gee A, et al. Alzheimer\u2019s disease biomarkers in Black and non-Hispanic White cohorts: a contextualized review of the evidence. Alzheimers Dement. 2022;18:1545\u201364.","journal-title":"Alzheimers Dement"},{"key":"819_CR190","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","volume":"76","author":"JC Morris","year":"2019","unstructured":"Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76:264\u201373.","journal-title":"JAMA Neurol"},{"key":"819_CR191","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"819_CR192","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvado","year":"2023","unstructured":"Salvado G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM, Zetterberg H, Mattsson-Carlgren N, Janelidze S, Blennow K, Hansson O. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15: e17123.","journal-title":"EMBO Mol Med"},{"key":"819_CR193","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"819_CR194","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1021\/jm030026b","volume":"46","author":"CA Mathis","year":"2003","unstructured":"Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740\u201354.","journal-title":"J Med Chem"},{"key":"819_CR195","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"819_CR196","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Dore V, Grinberg LT, Huang E, Hwang JH, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"819_CR197","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1007\/s00259-022-05808-7","volume":"49","author":"M Reinartz","year":"2022","unstructured":"Reinartz M, Luckett ES, Schaeverbeke J, De Meyer S, Adamczuk K, Thal DR, Van Laere K, Dupont P, Vandenberghe R. Classification of (18)F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth. Eur J Nucl Med Mol Imaging. 2022;49:3772\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"819_CR198","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915\u201324.","journal-title":"JAMA Neurol"},{"key":"819_CR199","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","volume":"14","author":"BJ Hanseeuw","year":"2018","unstructured":"Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, Jacobs HIL, Buckley RF, LaPoint MR, Vannini P, et al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14:1281\u201392.","journal-title":"Alzheimers Dement"},{"key":"819_CR200","doi-asserted-by":"publisher","first-page":"103321","DOI":"10.1016\/j.nicl.2023.103321","volume":"37","author":"ES Luckett","year":"2023","unstructured":"Luckett ES, Schaeverbeke J, De Meyer S, Adamczuk K, Van Laere K, Dupont P, Vandenberghe R. Longitudinal changes in (18)F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: methodological considerations. Neuroimage Clin. 2023;37:103321.","journal-title":"Neuroimage Clin"},{"key":"819_CR201","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.dadm.2018.12.008","volume":"11","author":"Y Su","year":"2019","unstructured":"Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement (Amst). 2019;11:180\u201390.","journal-title":"Alzheimers Dement (Amst)"},{"key":"819_CR202","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"VL Villemagne","year":"2011","unstructured":"Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181\u201392.","journal-title":"Ann Neurol"},{"key":"819_CR203","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1212\/WNL.0000000000004643","volume":"89","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, Alzheimer\u2019s Disease Neuroimaging I. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031\u20138.","journal-title":"Neurology"},{"key":"819_CR204","doi-asserted-by":"publisher","first-page":"e1692","DOI":"10.1212\/WNL.0000000000200148","volume":"98","author":"LE Collij","year":"2022","unstructured":"Collij LE, Salvado G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, Aksman L, Wink AM, Berckel BNM, van de Flier WM, et al. Spatial-temporal patterns of beta-amyloid accumulation: a subtype and stage inference model analysis. Neurology. 2022;98:e1692\u2013703.","journal-title":"Neurology"},{"key":"819_CR205","doi-asserted-by":"publisher","first-page":"e -1\u201316","DOI":"10.1016\/j.jalz.2013.01.002","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association. Alzheimers Dement. 2013;9:e-1-16.","journal-title":"Alzheimers Dement"},{"key":"819_CR206","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112\u201334.","journal-title":"Mol Psychiatry"},{"key":"819_CR207","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2967\/jnumed.116.185199","volume":"58","author":"L Declercq","year":"2017","unstructured":"Declercq L, Rombouts F, Koole M, Fierens K, Marien J, Langlois X, Andres JI, Schmidt M, Macdonald G, Moechars D, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58:975\u201381.","journal-title":"J Nucl Med"},{"key":"819_CR208","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2967\/jnumed.120.254961","volume":"63","author":"A Gogola","year":"2022","unstructured":"Gogola A, Minhas DS, Villemagne VL, Cohen AD, Mountz JM, Pascoal TA, Laymon CM, Mason NS, Ikonomovic MD, Mathis CA, et al. Direct comparison of the tau PET tracers (18)F-Flortaucipir and (18)F-MK-6240 in human subjects. J Nucl Med. 2022;63:108\u201316.","journal-title":"J Nucl Med"},{"key":"819_CR209","doi-asserted-by":"crossref","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, Aldea P, Flitter M, Locascio T, Devine M, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77:829-39.","DOI":"10.1001\/jamaneurol.2020.0528"},{"key":"819_CR210","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, Senjem ML, Schwarz CG, Kantarci K, Boeve B, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16:561\u201371.","journal-title":"Alzheimers Dement"},{"key":"819_CR211","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jogi J, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137.","journal-title":"Nat Med"},{"key":"819_CR212","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"819_CR213","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, O\u2019Neil JP, Janabi M, Lazaris A, Cantwell A, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain"},{"key":"819_CR214","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27:871\u201381.","journal-title":"Nat Med"},{"key":"819_CR215","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/alz.12321","volume":"17","author":"CM Moloney","year":"2021","unstructured":"Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 2021;17:1554\u201374.","journal-title":"Alzheimers Dement"},{"key":"819_CR216","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00259-019-04631-x","volume":"47","author":"J Schaeverbeke","year":"2020","unstructured":"Schaeverbeke J, Celen S, Cornelis J, Ronisz A, Serdons K, Van Laere K, Thal DR, Tousseyn T, Bormans G, Vandenberghe R. Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. Eur J Nucl Med Mol Imaging. 2020;47:1949\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"819_CR217","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2967\/jnumed.124.267539","volume":"66","author":"A Aliaga","year":"2025","unstructured":"Aliaga A, Therriault J, Quispialaya KM, Aliaga A, Hopewell R, Rahmouni N, Macedo AC, Kunach P, Soucy JP, Massarweh G, et al. Comparison between brain and cerebellar autoradiography using [(18)F]Flortaucipir, [(18)F]MK6240, and [(18)F]PI2620 in postmortem human brain tissue. J Nucl Med. 2025;66:123\u20139.","journal-title":"J Nucl Med"},{"key":"819_CR218","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, Kantarci K, Boeve BF, Pandey MK, Bruinsma T, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4:58.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR219","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-015-0220-4","volume":"3","author":"L Lemoine","year":"2015","unstructured":"Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, Okamura N, Nennesmo I, Gillberg PG, Nordberg A. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR220","first-page":"764","volume":"140","author":"M Ono","year":"2017","unstructured":"Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, Dickson DW, Trojanowski JQ, Lee VM, Yoshida M, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain. 2017;140:764\u201380.","journal-title":"Brain"},{"key":"819_CR221","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.24844","volume":"81","author":"M Marquie","year":"2017","unstructured":"Marquie M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea NV, Anton-Fernandez A, Klunk WE, Mathis CA, Ikonomovic MD, Debnath M, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81:117\u201328.","journal-title":"Ann Neurol"},{"key":"819_CR222","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40478-018-0535-z","volume":"6","author":"MC Wren","year":"2018","unstructured":"Wren MC, Lashley T, Arstad E, Sander K. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. Acta Neuropathol Commun. 2018;6:34.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR223","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12372","volume":"9","author":"JL Shuping","year":"2023","unstructured":"Shuping JL, Matthews DC, Adamczuk K, Scott D, Rowe CC, Kreisl WC, Johnson SC, Lukic AS, Johnson KA, Rosa-Neto P, et al. Development, initial validation, and application of a visual read method for [(18)F]MK-6240 tau PET. Alzheimers Dement (N Y). 2023;9: e12372.","journal-title":"Alzheimers Dement (N Y)"},{"key":"819_CR224","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41582-024-00962-y","volume":"20","author":"SJB Vos","year":"2024","unstructured":"Vos SJB, Delvenne A, Jack CR Jr, Thal DR, Visser PJ. The clinical importance of suspected non-Alzheimer disease pathophysiology. Nat Rev Neurol. 2024;20:337\u201346.","journal-title":"Nat Rev Neurol"},{"key":"819_CR225","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"819_CR226","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","volume":"60","author":"CM Clark","year":"2003","unstructured":"Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696\u2013702.","journal-title":"Arch Neurol"},{"key":"819_CR227","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"819_CR228","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3233\/JAD-191254","volume":"74","author":"G Banerjee","year":"2020","unstructured":"Banerjee G, Ambler G, Keshavan A, Paterson RW, Foiani MS, Toombs J, Heslegrave A, Dickson JC, Fraioli F, Groves AM, et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy. J Alzheimers Dis. 2020;74:1189\u2013201.","journal-title":"J Alzheimers Dis"},{"key":"819_CR229","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/archneurol.2012.26","volume":"69","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M. Comparison of cerebrospinal fluid levels of tau and Abeta 1\u201342 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol. 2012;69:1018\u201325.","journal-title":"Arch Neurol"},{"key":"819_CR230","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jalz.2014.12.006","volume":"11","author":"M Ewers","year":"2015","unstructured":"Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, Jessen F, Herukka SK, Soininen H, Maetzler W, et al. CSF biomarkers for the differential diagnosis of Alzheimer\u2019s disease: a large-scale international multicenter study. Alzheimers Dement. 2015;11:1306\u201315.","journal-title":"Alzheimers Dement"},{"key":"819_CR231","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1468-1331.2006.01593.x","volume":"14","author":"EN Kapaki","year":"2007","unstructured":"Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer\u2019s disease. Eur J Neurol. 2007;14:168\u201373.","journal-title":"Eur J Neurol"},{"key":"819_CR232","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1212\/WNL.0b013e31828c2fda","volume":"80","author":"A Jeppsson","year":"2013","unstructured":"Jeppsson A, Zetterberg H, Blennow K, Wikkelso C. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013;80:1385\u201392.","journal-title":"Neurology"},{"key":"819_CR233","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K, et al. CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"key":"819_CR234","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1212\/WNL.0000000000012513","volume":"97","author":"MJ Grothe","year":"2021","unstructured":"Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Scholl M. Alzheimer\u2019s Disease Neuroimaging I: Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. 2021;97:e1229\u201342.","journal-title":"Neurology"},{"key":"819_CR235","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-024-01758-3","volume":"12","author":"M Kurihara","year":"2024","unstructured":"Kurihara M, Matsubara T, Morimoto S, Arakawa A, Ohse K, Kanemaru K, Iwata A, Murayama S, Saito Y. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Abeta42 in Alzheimer\u2019s disease and other neurodegenerative diseases. Acta Neuropathol Commun. 2024;12:48.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR236","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acn3.697","volume":"6","author":"S Baiardi","year":"2019","unstructured":"Baiardi S, Abu-Rumeileh S, Rossi M, Zenesini C, Bartoletti-Stella A, Polischi B, Capellari S, Parchi P. Antemortem CSF Abeta42\/Abeta40 ratio predicts Alzheimer\u2019s disease pathology better than Abeta42 in rapidly progressive dementias. Ann Clin Transl Neurol. 2019;6:263\u201373.","journal-title":"Ann Clin Transl Neurol"},{"key":"819_CR237","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM. Cerebrospinal fluid Abeta42\/40 corresponds better than Abeta42 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:813\u201322.","journal-title":"J Alzheimers Dis"},{"key":"819_CR238","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0022-510X(98)00122-1","volume":"158","author":"M Shoji","year":"1998","unstructured":"Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, et al. Combination assay of CSF tau, A beta 1\u201340 and A beta 1\u201342(43) as a biochemical marker of Alzheimer\u2019s disease. J Neurol Sci. 1998;158:134\u201340.","journal-title":"J Neurol Sci"},{"key":"819_CR239","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K. Reference measurement procedure for CSF amyloid beta (Abeta)(1\u201342) and the CSF Abeta(1\u201342) \/Abeta(1\u201340) ratio - a cross-validation study against amyloid PET. J Neurochem. 2016;139:651\u20138.","journal-title":"J Neurochem"},{"key":"819_CR240","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382\u20139.","journal-title":"Arch Neurol"},{"key":"819_CR241","doi-asserted-by":"publisher","first-page":"e3104","DOI":"10.1212\/WNL.0000000000010747","volume":"95","author":"J Luo","year":"2020","unstructured":"Luo J, Agboola F, Grant E, Masters CL, Albert MS, Johnson SC, McDade EM, Voglein J, Fagan AM, Benzinger T, et al. Sequence of Alzheimer disease biomarker changes in cognitively normal adults: a cross-sectional study. Neurology. 2020;95:e3104\u201316.","journal-title":"Neurology"},{"key":"819_CR242","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O. Alzheimer\u2019s Disease Neuroimaging I: Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139:1226\u201336.","journal-title":"Brain"},{"key":"819_CR243","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer\u2019s disease. EMBO Mol Med. 2009;1:371\u201380.","journal-title":"EMBO Mol Med"},{"key":"819_CR244","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW, Alzheimer\u2019s Disease Neuroimaging I. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138:772\u201383.","journal-title":"Brain"},{"key":"819_CR245","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0009-8981(01)00573-3","volume":"310","author":"H Reiber","year":"2001","unstructured":"Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001;310:173\u201386.","journal-title":"Clin Chim Acta"},{"key":"819_CR246","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12640-018-9895-1","volume":"34","author":"SH Xin","year":"2018","unstructured":"Xin SH, Tan L, Cao X, Yu JT, Tan L. Clearance of amyloid beta and tau in Alzheimer\u2019s disease: from mechanisms to therapy. Neurotox Res. 2018;34:733\u201348.","journal-title":"Neurotox Res"},{"key":"819_CR247","doi-asserted-by":"publisher","first-page":"e70071","DOI":"10.1002\/dad2.70071","volume":"17","author":"S De Meyer","year":"2025","unstructured":"De Meyer S, Blujdea ER, Schaeverbeke JM, Adamczuk K, Vandenberghe R, Poesen K, Teunissen CE. Serum biomarkers as prognostic markers for Alzheimer\u2019s disease in a clinical setting. Alzheimers Dement (Amst). 2025;17:e70071.","journal-title":"Alzheimers Dement (Amst)"},{"key":"819_CR248","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease. Alzheimers Dement. 2009;5:18\u201329.","journal-title":"Alzheimers Dement"},{"key":"819_CR249","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nm.3810","volume":"21","author":"K Blennow","year":"2015","unstructured":"Blennow K, Zetterberg H. Understanding biomarkers of neurodegeneration: ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med. 2015;21:217\u20139.","journal-title":"Nat Med"},{"key":"819_CR250","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simren J, Lantero-Rodriguez J, Karikari TK, Hiniker A, Rissman RA, Salmon DP, Galasko D. Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143:487\u2013503.","journal-title":"Acta Neuropathol"},{"key":"819_CR251","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00401-023-02594-w","volume":"146","author":"C Bermudez","year":"2023","unstructured":"Bermudez C, Graff-Radford J, Syrjanen JA, Stricker NH, Algeciras-Schimnich A, Kouri N, Kremers WK, Petersen RC, Jack CR Jr, Knopman DS, et al. Plasma biomarkers for prediction of Alzheimer\u2019s disease neuropathologic change. Acta Neuropathol. 2023;146:13\u201329.","journal-title":"Acta Neuropathol"},{"key":"819_CR252","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, Ossenkoppele R, Jonsson M, Seeley W, Ehrenberg A, Spina S, Janelidze S, Rojas-Martinex J, et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2022;98:e1137\u201350.","journal-title":"Neurology"},{"key":"819_CR253","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allue JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, et al. Head-to-head comparison of 8 plasma amyloid-beta 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375\u201382.","journal-title":"JAMA Neurol"},{"key":"819_CR254","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","volume":"12","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Schaeverbeke JM, Verberk IMW, Gille B, De Schaepdryver M, Luckett ES, Gabel S, Bruffaerts R, Mauroo K, Thijssen EH, et al. Comparison of ELISA- and SIMOA-based quantification of plasma Abeta ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther. 2020;12:162.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR255","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841\u20139.","journal-title":"Alzheimers Dement"},{"key":"819_CR256","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, Fowler C, Li QX, Martins R, Rowe C, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature"},{"key":"819_CR257","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647\u201359.","journal-title":"Neurology"},{"key":"819_CR258","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep"},{"key":"819_CR259","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84:648\u201358.","journal-title":"Ann Neurol"},{"key":"819_CR260","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","volume":"15","author":"A Vergallo","year":"2019","unstructured":"Vergallo A, Megret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, et al. Plasma amyloid beta 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease. Alzheimers Dement. 2019;15:764\u201375.","journal-title":"Alzheimers Dement"},{"key":"819_CR261","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M, Group AR","year":"2017","unstructured":"Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M, Group AR. Plasma amyloid beta 42\/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179\u201387.","journal-title":"Alzheimers Dement (Amst)"},{"key":"819_CR262","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","volume":"96","author":"I Illan-Gala","year":"2021","unstructured":"Illan-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, Grinberg LT, Spina S, Kramer JH, Ramos EM, et al. Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology. 2021;96:e671\u201383.","journal-title":"Neurology"},{"key":"819_CR263","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","volume":"76","author":"MP Pase","year":"2019","unstructured":"Pase MP, Beiser AS, Himali JJ, Satizabal CL, Aparicio HJ, DeCarli C, Chene G, Dufouil C, Seshadri S. Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019;76:598\u2013606.","journal-title":"JAMA Neurol"},{"key":"819_CR264","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87:1827\u201335.","journal-title":"Neurology"},{"key":"819_CR265","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O. Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5:9.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR266","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E, Alzheimer\u2019s Disease Neuroimaging I, Swedish Bio Fs, Mattsson N, Hansson O. Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019;15:194\u2013204.","journal-title":"Alzheimers Dement"},{"key":"819_CR267","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ene.13389","volume":"24","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Andreasson U, Liman V, Regelsberger G, Lutz MI, Danics K, Keller E, Zetterberg H, Blennow K. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017;24:1326-e1377.","journal-title":"Eur J Neurol"},{"key":"819_CR268","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mila-Aloma M, Fernandez-Lebrero A, Garcia-Escobar G, Gonzalez-Ortiz F, Kac PR, Brum WS, Benedet AL, Lantero-Rodriguez J, et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19:1913\u201324.","journal-title":"Alzheimers Dement"},{"key":"819_CR269","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, Bourakova V, Cobigo Y, Heuer H, Spina S, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"819_CR270","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, Aarsland D, Hye A, Zetterberg H, Blennow K, Ashton NJ. Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140:267\u201378.","journal-title":"Acta Neuropathol"},{"key":"819_CR271","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow K, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11: e11170.","journal-title":"EMBO Mol Med"},{"key":"819_CR272","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/acn3.51768","volume":"10","author":"KAQ Cousins","year":"2023","unstructured":"Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, Wolk DA, Weintraub D, Spindler M, Deik A, et al. Plasma GFAP associates with secondary Alzheimer\u2019s pathology in Lewy body disease. Ann Clin Transl Neurol. 2023;10:802\u201313.","journal-title":"Ann Clin Transl Neurol"},{"key":"819_CR273","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acn3.51553","volume":"9","author":"S De Meyer","year":"2022","unstructured":"De Meyer S, Vanbrabant J, Schaeverbeke JM, Reinartz M, Luckett ES, Dupont P, Van Laere K, Stoops E, Vanmechelen E, Poesen K, Vandenberghe R. Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2022;9:734\u201346.","journal-title":"Ann Clin Transl Neurol"},{"key":"819_CR274","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Scholl M, Troakes C, Hye A, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"819_CR275","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonzalez-Ortiz F, Di Molfetta G, Meda FJ, et al. Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"key":"819_CR276","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, Salvado G, Minguillon C, Fauria K, Shekari M, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med. 2020;12: e12921.","journal-title":"EMBO Mol Med"},{"key":"819_CR277","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12:26.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR278","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, Proctor NK, Chai X, Shcherbinin S, Sims JR, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11:1683.","journal-title":"Nat Commun"},{"key":"819_CR279","doi-asserted-by":"publisher","first-page":"e3026","DOI":"10.1212\/WNL.0000000000010814","volume":"95","author":"J Hanes","year":"2020","unstructured":"Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, et al. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. 2020;95:e3026\u201335.","journal-title":"Neurology"},{"key":"819_CR280","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"819_CR281","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, Karikari TK, Vanmechelen E, Zetterberg H, Algeciras-Schimnich A, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78:1108\u201317.","journal-title":"JAMA Neurol"},{"key":"819_CR282","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/alz.12236","volume":"17","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Emersic A, Vrillon A, Lantero-Rodriguez J, Ashton NJ, Kramberger MG, Dumurgier J, Hourregue C, Cucnik S, Brinkmalm G, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimers Dement. 2021;17:755\u201367.","journal-title":"Alzheimers Dement"},{"key":"819_CR283","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barthelemy","year":"2023","unstructured":"Barthelemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, Stomrud E, Salvado G, Janelidze S, Sato C, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat Aging. 2023;3:391\u2013401.","journal-title":"Nat Aging"},{"key":"819_CR284","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, Ashton NJ, Zetterberg H, Blennow K, Vanbrabant J, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13:198.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR285","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601.","journal-title":"Brain"},{"key":"819_CR286","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, Edwards L, Eser R, Gorno-Tempini ML, Jagust WJ, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain. 2020;143:3477\u201394.","journal-title":"Brain"},{"key":"819_CR287","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-021-00798-4","volume":"13","author":"JM Schaeverbeke","year":"2021","unstructured":"Schaeverbeke JM, Gabel S, Meersmans K, Luckett ES, De Meyer S, Adamczuk K, Nelissen N, Goovaerts V, Radwan A, Sunaert S, et al. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. Alzheimers Res Ther. 2021;13:75.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR288","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, Palmqvist S, Olsson T, Jogi J, Stormrud E, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"819_CR289","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/brain\/awaa373","volume":"144","author":"K Horie","year":"2021","unstructured":"Horie K, Barthelemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain. 2021;144:515\u201327.","journal-title":"Brain"},{"key":"819_CR290","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvado G, Barthelemy NR, Janelidze S, Li Y, He Y, Saef B, Chen CD, Jiang H, Strandberg O, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29:1954\u201363.","journal-title":"Nat Med"},{"key":"819_CR291","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","volume":"4","author":"G Salvado","year":"2024","unstructured":"Salvado G, Horie K, Barthelemy NR, Vogel JW, Pichet Binette A, Chen CD, Aschenbrenner AJ, Gordon BA, Benzinger TLS, Holtzman DM, et al. Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model. Nat Aging. 2024;4:694\u2013708.","journal-title":"Nat Aging"},{"key":"819_CR292","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med. 2020;26:398\u2013407.","journal-title":"Nat Med"},{"key":"819_CR293","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, Benussi L, Cantoni V, Saraceno C, Rivolta J, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain. 2023;146:1152\u201365.","journal-title":"Brain"},{"key":"819_CR294","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, Kirsebom BE, Contador J, Tanley JE, Selnes P, Gisladottir B, Palhaugen L, Suhr Hemminghyth M, Jarholm J, Skogseth R, et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease. Nat Commun. 2024;15:2908.","journal-title":"Nat Commun"},{"key":"819_CR295","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/brain\/awad330","volume":"147","author":"S De Meyer","year":"2024","unstructured":"De Meyer S, Blujdea ER, Schaeverbeke J, Reinartz M, Luckett ES, Adamczuk K, Van Laere K, Dupont P, Teunissen CE, Vandenberghe R, Poesen K. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes. Brain. 2024;147:936\u201348.","journal-title":"Brain"},{"key":"819_CR296","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, Verberk IMW, Dave P, Taddei K, Sohrabi HR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11:27.","journal-title":"Transl Psychiatry"},{"key":"819_CR297","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, Scheltens P, Teunissen CE, van der Flier WM. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2:e87\u201395.","journal-title":"Lancet Healthy Longev"},{"key":"819_CR298","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo Y, You J, Zhang Y, Liu WS, Huang YY, Zhang YR, Zhang W, Dong Q, Feng JF, Cheng W, Yu JT. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024;4:247\u201360.","journal-title":"Nat Aging"},{"key":"819_CR299","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp-2021-328547","volume":"93","author":"P Oeckl","year":"2022","unstructured":"Oeckl P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, Diehl-Schmid J, Grimmer T, Halbgebauer S, Kort AM, Lima M, Marques TM, et al. Serum GFAP differentiates Alzheimer\u2019s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry. 2022;93:659\u201367.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"819_CR300","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40035-021-00275-w","volume":"10","author":"N Zhu","year":"2021","unstructured":"Zhu N, Santos-Santos M, Illan-Gala I, Montal V, Estelles T, Barroeta I, Altuna M, Arranz J, Munoz L, Belbin O, et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Transl Neurodegener. 2021;10:50.","journal-title":"Transl Neurodegener"},{"key":"819_CR301","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O. Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316.","journal-title":"Brain"},{"key":"819_CR302","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1002\/alz.13777","volume":"20","author":"KAQ Cousins","year":"2024","unstructured":"Cousins KAQ, Phillips JS, Das SR, O\u2019Brien K, Tropea TF, Chen-Plotkin A, Shaw LM, Nasrallah IM, Mechanic-Hamilton D, McMillan CT, et al. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease. Alzheimers Dement. 2024;20:3889\u2013905.","journal-title":"Alzheimers Dement"},{"key":"819_CR303","first-page":"86","volume":"132","author":"DW Dickson","year":"1988","unstructured":"Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer\u2019s disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol. 1988;132:86\u2013101.","journal-title":"Am J Pathol"},{"key":"819_CR304","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00005072-199703000-00007","volume":"56","author":"JG Sheng","year":"1997","unstructured":"Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol. 1997;56:285\u201390.","journal-title":"J Neuropathol Exp Neurol"},{"key":"819_CR305","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mila-Aloma M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471\u201383.","journal-title":"JAMA Neurol"},{"key":"819_CR306","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-019-0545-5","volume":"11","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Suarez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, et al. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther. 2019;11:94.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR307","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925\u201333.","journal-title":"Acta Neuropathol"},{"key":"819_CR308","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mila-Aloma","year":"2020","unstructured":"Mila-Aloma M, Salvado G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, Sanchez-Benavides G, Arenaza-Urquijo EM, Crous-Bou M, Gonzalez-de-Echavarri JM, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement. 2020;16:1358\u201371.","journal-title":"Alzheimers Dement"},{"key":"819_CR309","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","volume":"16","author":"A Villar-Pique","year":"2019","unstructured":"Villar-Pique A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, Ferrer I, Riggert J, Llorens F, Zerr I. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16:145.","journal-title":"J Neuroinflammation"},{"key":"819_CR310","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jnc.14680","volume":"149","author":"J Schaeverbeke","year":"2019","unstructured":"Schaeverbeke J, Gille B, Adamczuk K, Vanderstichele H, Chassaing E, Bruffaerts R, Neyens V, Stoops E, Tournoy J, Vandenberghe R, Poesen K. Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. J Neurochem. 2019;149:139\u201357.","journal-title":"J Neurochem"},{"key":"819_CR311","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1212\/WNL.0b013e318247caa1","volume":"78","author":"M Watabe-Rudolph","year":"2012","unstructured":"Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus-Nahrmann Y, Scheithauer MO, Rettinger G, Otto M, Tumani H, Thal DR, et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology. 2012;78:569\u201377.","journal-title":"Neurology"},{"key":"819_CR312","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/STROKEAHA.123.044719","volume":"55","author":"RA Martirosian","year":"2024","unstructured":"Martirosian RA, Wiedner CD, Sanchez J, Mun KT, Marla K, Teran C, Thirion M, Liebeskind DS, McGrath ER, Zucker JM, et al. Association of incident stroke risk with an IL-18-centered inflammatory network biomarker composite. Stroke. 2024;55:1601\u20138.","journal-title":"Stroke"},{"key":"819_CR313","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227835","volume":"15","author":"M Altendahl","year":"2020","unstructured":"Altendahl M, Maillard P, Harvey D, Cotter D, Walters S, Wolf A, Singh B, Kakarla V, Azizkhanian I, Sheth SA, et al. An IL-18-centered inflammatory network as a biomarker for cerebral white matter injury. PLoS One. 2020;15: e0227835.","journal-title":"PLoS One"},{"key":"819_CR314","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-94","volume":"11","author":"P Italiani","year":"2014","unstructured":"Italiani P, Carlesi C, Giungato P, Puxeddu I, Borroni B, Bossu P, Migliorini P, Siciliano G, Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation. 2014;11: 94.","journal-title":"J Neuroinflammation"},{"key":"819_CR315","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1038\/s41598-023-35945-4","volume":"13","author":"HC Lok","year":"2023","unstructured":"Lok HC, Katzeff JS, Hodges JR, Piguet O, Fu Y, Halliday GM, Kim WS. Elevated GRO-alpha and IL-18 in serum and brain implicate the NLRP3 inflammasome in frontotemporal dementia. Sci Rep. 2023;13:8942.","journal-title":"Sci Rep"},{"key":"819_CR316","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.4103\/1673-5374.300986","volume":"16","author":"RM Corbo","year":"2021","unstructured":"Corbo RM, Businaro R, Scarabino D. Leukocyte telomere length and plasma interleukin-1beta and interleukin-18 levels in mild cognitive impairment and Alzheimer\u2019s disease: new biomarkers for diagnosis and disease progression? Neural Regen Res. 2021;16:1397\u20138.","journal-title":"Neural Regen Res"},{"key":"819_CR317","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2967\/jnumed.121.263254","volume":"63","author":"VL Villemagne","year":"2022","unstructured":"Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, Burnham S, Krishnadas N, Bozinovski S, Huang K, et al. First-in-humans evaluation of (18)F-SMBT-1, a novel (18)F-labeled monoamine oxidase-B PET tracer for imaging reactive astrogliosis. J Nucl Med. 2022;63:1551\u20139.","journal-title":"J Nucl Med"},{"key":"819_CR318","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"AR Gafson","year":"2020","unstructured":"Gafson AR, Barthelemy NR, Bomont P, Carare RO, Durham HD, Julien JP, Kuhle J, Leppert D, Nixon RA, Weller RO, et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020;143:1975\u201398.","journal-title":"Brain"},{"key":"819_CR319","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"819_CR320","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, Liman V, Norgren N, Blennow K, Zetterberg H. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655\u201361.","journal-title":"Clin Chem Lab Med"},{"key":"819_CR321","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u201389.","journal-title":"Nat Rev Neurol"},{"key":"819_CR322","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.689938","volume":"15","author":"A Yuan","year":"2021","unstructured":"Yuan A, Nixon RA. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front Neurosci. 2021;15: 689938.","journal-title":"Front Neurosci"},{"key":"819_CR323","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, Wermeling P, Sedaghat S, Ikram MK, Waziry R, et al. Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study. Brain. 2020;143:1220\u201332.","journal-title":"Brain"},{"key":"819_CR324","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12916-024-03418-8","volume":"22","author":"X Wang","year":"2024","unstructured":"Wang X, Shi Z, Qiu Y, Sun D, Zhou H. Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC Med. 2024;22:192.","journal-title":"BMC Med"},{"key":"819_CR325","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2022.07.006","volume":"119","author":"J Graff-Radford","year":"2022","unstructured":"Graff-Radford J, Mielke MM, Hofrenning EI, Kouri N, Lesnick TG, Moloney CM, Rabinstein A, Cabrera-Rodriguez JN, Rothberg DM, Przybelski SA, et al. Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer\u2019s disease. Neurobiol Aging. 2022;119:1\u20137.","journal-title":"Neurobiol Aging"},{"key":"819_CR326","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1212\/WNL.0000000000207419","volume":"101","author":"A Dittrich","year":"2023","unstructured":"Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Zettergren A, Simren J, Skillback T, Shams S, Machado A, Westman E, et al. Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration: the H70 birth cohort study in Gothenburg. Neurology. 2023;101:e277\u201388.","journal-title":"Neurology"},{"key":"819_CR327","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.26446","volume":"92","author":"KC Fitzgerald","year":"2022","unstructured":"Fitzgerald KC, Sotirchos ES, Smith MD, Lord HN, DuVal A, Mowry EM, Calabresi PA. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol. 2022;92:688\u201398.","journal-title":"Ann Neurol"},{"key":"819_CR328","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","volume":"68","author":"SW Scheff","year":"2007","unstructured":"Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501\u20138.","journal-title":"Neurology"},{"key":"819_CR329","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jalz.2016.04.005","volume":"12","author":"E Bereczki","year":"2016","unstructured":"Bereczki E, Francis PT, Howlett D, Pereira JB, Hoglund K, Bogstedt A, Cedazo-Minguez A, Baek JH, Hortobagyi T, Attems J, et al. Synaptic proteins predict cognitive decline in Alzheimer\u2019s disease and Lewy body dementia. Alzheimers Dement. 2016;12:1149\u201358.","journal-title":"Alzheimers Dement"},{"key":"819_CR330","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572\u201380.","journal-title":"Ann Neurol"},{"key":"819_CR331","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457\u201364.","journal-title":"Ann Neurol"},{"key":"819_CR332","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/alz.12809","volume":"19","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, Grossman M, Irwin DJ, Trojanowski JQ, Zetterberg H, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer\u2019s disease and other neurodegenerative disorders. Alzheimers Dement. 2023;19:1775\u201384.","journal-title":"Alzheimers Dement"},{"key":"819_CR333","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-024-01409-8","volume":"16","author":"S Das","year":"2024","unstructured":"Das S, van Engelen ME, Goossens J, Jacobs D, Bongers B, Fieldhouse JLP, Pijnenburg YAL, Teunissen CE, Vanmechelen E, Verberk IMW. The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:34.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR334","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson J, Pichet Binette A, Palmqvist S, Brum WS, Janelidze S, Ashton NJ, Spotorno N, Stomrud E, Gobom J, Zetterberg H, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain. 2024;147:2414\u201327.","journal-title":"Brain"},{"key":"819_CR335","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","volume":"15","author":"S Das","year":"2023","unstructured":"Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, In \u2019t Veld S, Teunissen CE, Vanmechelen E. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15:62.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR336","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-019-0564-2","volume":"11","author":"MTM Clarke","year":"2019","unstructured":"Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, Keshavan A, Fox NC, Schott JM, Warren JD, et al. CSF synaptic protein concentrations are raised in those with atypical Alzheimer\u2019s disease but not frontotemporal dementia. Alzheimers Res Ther. 2019;11:105.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR337","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1212\/WNL.0000000000207371","volume":"101","author":"L Barba","year":"2023","unstructured":"Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, Oeckl P, Steinacker P, Massa F, Parnetti L, Otto M. CSF synaptic biomarkers in AT(N)-based subgroups of Lewy body disease. Neurology. 2023;101:e50\u201362.","journal-title":"Neurology"},{"key":"819_CR338","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-022-01002-x","volume":"14","author":"P Kivisakk","year":"2022","unstructured":"Kivisakk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, Mendes M, Brock M, Rubel C, Czerkowicz J, et al. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:58.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR339","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1002\/alz.13046","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, Ashton NJ, Molfetta GD, Grotschel L, Kivipelto M, et al. Blood beta-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimers Dement. 2023;19:4896\u2013907.","journal-title":"Alzheimers Dement"},{"key":"819_CR340","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1002\/alz.13103","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, Hansson O. Higher plasma beta-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:5095\u2013102.","journal-title":"Alzheimers Dement"},{"key":"819_CR341","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-022-01014-7","volume":"14","author":"A Vrillon","year":"2022","unstructured":"Vrillon A, Mouton-Liger F, Martinet M, Cognat E, Hourregue C, Dumurgier J, Bouaziz-Amar E, Brinkmalm A, Blennow K, Zetterberg H, et al. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer\u2019s disease: a discovery cohort study. Alzheimers Res Ther. 2022;14:71.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR342","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.04.012","volume":"97","author":"KA Chang","year":"2016","unstructured":"Chang KA, Shin KY, Nam E, Lee YB, Moon C, Suh YH, Lee SH. Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer\u2019s disease. Neurochem Int. 2016;97:1\u20137.","journal-title":"Neurochem Int"},{"key":"819_CR343","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.2967\/jnumed.121.263201","volume":"63","author":"RE Carson","year":"2022","unstructured":"Carson RE, Naganawa M, Toyonaga T, Koohsari S, Yang Y, Chen MK, Matuskey D, Finnema SJ. Imaging of synaptic density in neurodegenerative disorders. J Nucl Med. 2022;63:60S-67S.","journal-title":"J Nucl Med"},{"key":"819_CR344","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00401-024-02816-9","volume":"148","author":"M Shanaki Bavarsad","year":"2024","unstructured":"Shanaki Bavarsad M, Spina S, Oehler A, Allen IE, Suemoto CK, Leite REP, Seeley WS, Green A, Jagust W, Rabinovici GD, Grinberg LT. Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation. Acta Neuropathol. 2024;148:58.","journal-title":"Acta Neuropathol"},{"key":"819_CR345","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/alz.13720","volume":"20","author":"A Kumar","year":"2024","unstructured":"Kumar A, Scarpa M, Nordberg A. Tracing synaptic loss in Alzheimer\u2019s brain with SV2A PET-tracer UCB-J. Alzheimers Dement. 2024;20:2589\u2013605.","journal-title":"Alzheimers Dement"},{"key":"819_CR346","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/alz.13529","volume":"20","author":"J Alber","year":"2024","unstructured":"Alber J, Bouwman F, den Haan J, Rissman RA, De Groef L, Koronyo-Hamaoui M, Lengyel I, Thal DR, Alzheimer\u2019s Association ITEaaBfADPIA. Retina pathology as a target for biomarkers for Alzheimer\u2019s disease: current status, ophthalmopathological background, challenges, and future directions. Alzheimers Dement. 2024;20:728\u201340.","journal-title":"Alzheimers Dement"},{"key":"819_CR347","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/alz.12179","volume":"17","author":"PJ Snyder","year":"2021","unstructured":"Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, DeBuc DC, Campbell MCW, Carrillo MC, Chew EY, et al. Retinal imaging in Alzheimer\u2019s and neurodegenerative diseases. Alzheimers Dement. 2021;17:103\u201311.","journal-title":"Alzheimers Dement"},{"key":"819_CR348","first-page":"e12119","volume":"12","author":"J Alber","year":"2020","unstructured":"Alber J, Arthur E, Sinoff S, DeBuc DC, Chew EY, Douquette L, Hatch WV, Hudson C, Kashani A, Lee CS, et al. A recommended \u201cminimum data set\u201d framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer\u2019s Study (ARIAS). Alzheimers Dement (Amst). 2020;12:e12119.","journal-title":"Alzheimers Dement (Amst)"},{"key":"819_CR349","doi-asserted-by":"publisher","first-page":"e0134750","DOI":"10.1371\/journal.pone.0134750","volume":"10","author":"G Coppola","year":"2015","unstructured":"Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G, Barboni P, Pierelli F, Sadun AA, Parisi V. Optical coherence tomography in Alzheimer\u2019s disease: a meta-analysis. PLoS One. 2015;10:e0134750.","journal-title":"PLoS One"},{"key":"819_CR350","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3389\/fneur.2017.00701","volume":"8","author":"J Doustar","year":"2017","unstructured":"Doustar J, Torbati T, Black KL, Koronyo Y, Koronyo-Hamaoui M. Optical coherence tomography in Alzheimer\u2019s disease and other neurodegenerative diseases. Front Neurol. 2017;8:701.","journal-title":"Front Neurol"},{"key":"819_CR351","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaophthalmol.2018.3556","volume":"136","author":"BE O'Bryhim","year":"2018","unstructured":"O\u2019Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmol. 2018;136:1242\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"819_CR352","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/bjophthalmol-2020-317659","volume":"106","author":"CE Wisely","year":"2022","unstructured":"Wisely CE, Wang D, Henao R, Grewal DS, Thompson AC, Robbins CB, Yoon SP, Soundararajan S, Polascik BW, Burke JR, et al. Convolutional neural network to identify symptomatic Alzheimer\u2019s disease using multimodal retinal imaging. Br J Ophthalmol. 2022;106:388\u201395.","journal-title":"Br J Ophthalmol"},{"key":"819_CR353","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41467-019-12242-1","volume":"10","author":"X Hadoux","year":"2019","unstructured":"Hadoux X, Hui F, Lim JKH, Masters CL, Pebay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, et al. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer\u2019s disease. Nat Commun. 2019;10:4227.","journal-title":"Nat Commun"},{"key":"819_CR354","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13195-020-00715-1","volume":"12","author":"S Lemmens","year":"2020","unstructured":"Lemmens S, Van Craenendonck T, Van Eijgen J, De Groef L, Bruffaerts R, de Jesus DA, Charle W, Jayapala M, Sunaric-Megevand G, Standaert A, et al. Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer\u2019s disease patients. Alzheimers Res Ther. 2020;12:144.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR355","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1021\/acschemneuro.9b00331","volume":"10","author":"SS More","year":"2019","unstructured":"More SS, Beach JM, McClelland C, Mokhtarzadeh A, Vince R. In vivo assessment of retinal biomarkers by hyperspectral imaging: early detection of Alzheimer\u2019s disease. ACS Chem Neurosci. 2019;10:4492\u2013501.","journal-title":"ACS Chem Neurosci"},{"key":"819_CR356","doi-asserted-by":"publisher","first-page":"pgac164","DOI":"10.1093\/pnasnexus\/pgac164","volume":"1","author":"X Du","year":"2022","unstructured":"Du X, Koronyo Y, Mirzaei N, Yang C, Fuchs DT, Black KL, Koronyo-Hamaoui M, Gao L. Label-free hyperspectral imaging and deep-learning prediction of retinal amyloid beta-protein and phosphorylated tau. PNAS Nexus. 2022;1:pgac164.","journal-title":"PNAS Nexus"},{"key":"819_CR357","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2174\/15672050113109990002","volume":"10","author":"J Attems","year":"2013","unstructured":"Attems J, Jellinger K. Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res. 2013;10:569\u201377.","journal-title":"Curr Alzheimer Res"},{"key":"819_CR358","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209418","volume":"102","author":"K Bolsewig","year":"2024","unstructured":"Bolsewig K, van Unnik A, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D, Zetterberg H, Padovani A, Bonanni L, Mollenhauer B, et al. Association of plasma amyloid, P-Tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with Lewy bodies. Neurology. 2024;102: e209418.","journal-title":"Neurology"},{"key":"819_CR359","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith R, Capotosti F, Schain M, Ohlsson T, Vokali E, Molette J, Touilloux T, Hliva V, Dimitrakopoulos IK, Puschmann A, et al. The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun. 2023;14:6750.","journal-title":"Nat Commun"},{"issue":"2540\u20132557","key":"819_CR360","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo H, Ono M, Takado Y, Matsuoka K, Takahashi M, Tagai K, Kataoka Y, Hirata K, Takahata K, Seki C, et al. Imaging alpha-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron. 2024;112(2540\u20132557): e2548.","journal-title":"Neuron"},{"key":"819_CR361","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105807","volume":"117","author":"B Fernandes Gomes","year":"2023","unstructured":"Fernandes Gomes B, Farris CM, Ma Y, Concha-Marambio L, Lebovitz R, Nellgard B, Dalla K, Constantinescu J, Constantinescu R, Gobom J, et al. alpha-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. Parkinsonism Relat Disord. 2023;117: 105807.","journal-title":"Parkinsonism Relat Disord"},{"key":"819_CR362","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1002\/alz.13799","volume":"20","author":"N Samudra","year":"2024","unstructured":"Samudra N, Fischer DL, Lenio S, Lario Lago A, Ljubenkov PA, Rojas JC, Seeley WW, Spina S, Staffaroni AM, Tablante J, et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. Alzheimers Dement. 2024;20:3334\u201341.","journal-title":"Alzheimers Dement"},{"key":"819_CR363","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orru CD, Antelmi E, Mammana A, Hughson AG, Calandra-Buonaura G, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140:49\u201362.","journal-title":"Acta Neuropathol"},{"key":"819_CR364","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/acn3.50897","volume":"6","author":"M Bongianni","year":"2019","unstructured":"Bongianni M, Ladogana A, Capaldi S, Klotz S, Baiardi S, Cagnin A, Perra D, Fiorini M, Poleggi A, Legname G, et al. alpha-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Ann Clin Transl Neurol. 2019;6:2120\u20136.","journal-title":"Ann Clin Transl Neurol"},{"key":"819_CR365","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.26453","volume":"92","author":"MR Arnold","year":"2022","unstructured":"Arnold MR, Coughlin DG, Brumbach BH, Smirnov DS, Concha-Marambio L, Farris CM, Ma Y, Kim Y, Wilson EN, Kaye JA, et al. alpha-Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological alpha-Synuclein in the context of co-pathology and non-LBD diagnoses. Ann Neurol. 2022;92:650\u201362.","journal-title":"Ann Neurol"},{"key":"819_CR366","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/mds.28242","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne S, Kondru N, Jin H, Serrano GE, Anantharam V, Kanthasamy A, Adler CH, Beach TG, Kanthasamy AG. Blinded RT-QuIC analysis of alpha-Synuclein biomarker in skin tissue from Parkinson\u2019s disease patients. Mov Disord. 2020;35:2230\u20139.","journal-title":"Mov Disord"},{"key":"819_CR367","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.28651","volume":"36","author":"A Mammana","year":"2021","unstructured":"Mammana A, Baiardi S, Quadalti C, Rossi M, Donadio V, Capellari S, Liguori R, Parchi P. RT-QuIC detection of pathological alpha-Synuclein in skin punches of patients with Lewy body disease. Mov Disord. 2021;36:2173\u20137.","journal-title":"Mov Disord"},{"key":"819_CR368","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","volume":"100","author":"A Iranzo","year":"2023","unstructured":"Iranzo A, Mammana A, Munoz-Lopetegi A, Dellavalle S, Maya G, Rossi M, Serradell M, Baiardi S, Arqueros A, Quadalti C, et al. Misfolded alpha-Synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. Neurology. 2023;100:e1944\u201354.","journal-title":"Neurology"},{"key":"819_CR369","doi-asserted-by":"publisher","first-page":"18914","DOI":"10.1074\/jbc.RA118.005603","volume":"293","author":"ZA Sorrentino","year":"2018","unstructured":"Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J, Giasson BI. Physiological C-terminal truncation of alpha-synuclein potentiates the prion-like formation of pathological inclusions. J Biol Chem. 2018;293:18914\u201332.","journal-title":"J Biol Chem"},{"key":"819_CR370","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall S, Orru CD, Serrano GE, Galasko D, Hughson AG, Groveman BR, Adler CH, Beach TG, Caughey B, Hansson O. Performance of alphaSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathol Commun. 2022;10:90.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR371","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"819_CR372","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge A, Bunk J, Schaeffer E, Drobny A, Xiang W, Knacke H, Bub S, Luckstadt W, Arnold P, Lucius R, et al. Detection of neuron-derived pathological alpha-synuclein in blood. Brain. 2022;145:3058\u201371.","journal-title":"Brain"},{"key":"819_CR373","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, et al. Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. 2023;29:1448\u201355.","journal-title":"Nat Med"},{"key":"819_CR374","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181\u201393.","journal-title":"Brain"},{"key":"819_CR375","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, et al. TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathol. 2014;127:811\u201324.","journal-title":"Acta Neuropathol"},{"key":"819_CR376","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ana.24493","volume":"78","author":"KA Josephs","year":"2015","unstructured":"Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer\u2019s disease impact clinical features. Ann Neurol. 2015;78:697\u2013709.","journal-title":"Ann Neurol"},{"key":"819_CR377","doi-asserted-by":"publisher","DOI":"10.1002\/alz.075525","volume":"19","author":"T Seredenina","year":"2023","unstructured":"Seredenina T, Vokali E, Dreyfus N, Chevallier E, Afroz T, Jaquier T, Serra AM, Clavel M, Rathnam M, Melly T, et al. Discovery and optimization of the first-in-class TDP-43 PET tracer. Alzheimers Dement. 2023;19: e075525.","journal-title":"Alzheimers Dement"},{"key":"819_CR378","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/alz.12878","volume":"19","author":"AF Carlos","year":"2023","unstructured":"Carlos AF, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, Knopman DS, Boeve BF, Petersen RC, Nguyen AT, Reichard RR, et al. TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:2343\u201354.","journal-title":"Alzheimers Dement"},{"key":"819_CR379","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00401-008-0389-8","volume":"116","author":"P Foulds","year":"2008","unstructured":"Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D, Snowden JS, Allsop D, Mann DM. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Acta Neuropathol. 2008;116:141\u20136.","journal-title":"Acta Neuropathol"},{"key":"819_CR380","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-008-0456-1","volume":"117","author":"T Kasai","year":"2009","unstructured":"Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, Mann DM, Allsop D, Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55\u201362.","journal-title":"Acta Neuropathol"},{"key":"819_CR381","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/17482968.2010.541263","volume":"12","author":"Y Noto","year":"2011","unstructured":"Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, Mori M, Uchiyama T, Isose S, Nasu S, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011;12:140\u20133.","journal-title":"Amyotroph Lateral Scler"},{"key":"819_CR382","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/00207454.2013.848440","volume":"124","author":"M Hosokawa","year":"2014","unstructured":"Hosokawa M, Arai T, Yamashita M, Tsuji H, Nonaka T, Masuda-Suzukake M, Tamaoka A, Hasegawa M, Akiyama H. Differential diagnosis of amyotrophic lateral sclerosis from Guillain-Barre syndrome by quantitative determination of TDP-43 in cerebrospinal fluid. Int J Neurosci. 2014;124:344\u20139.","journal-title":"Int J Neurosci"},{"key":"819_CR383","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3109\/17482968.2012.703208","volume":"13","author":"E Verstraete","year":"2012","unstructured":"Verstraete E, Kuiperij HB, van Blitterswijk MM, Veldink JH, Schelhaas HJ, van den Berg LH, Verbeek MM. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:446\u201351.","journal-title":"Amyotroph Lateral Scler"},{"key":"819_CR384","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/jnnp-2013-305972","volume":"85","author":"M Suarez-Calvet","year":"2014","unstructured":"Suarez-Calvet M, Dols-Icardo O, Llado A, Sanchez-Valle R, Hernandez I, Amer G, Anton-Aguirre S, Alcolea D, Fortea J, Ferrer I, et al. Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry. 2014;85:684\u201391.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"819_CR385","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.663637","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren Y, Li S, Chen S, Sun X, Yang F, Wang H, Li M, Cui F, Huang X. TDP-43 and phosphorylated TDP-43 levels in paired plasma and CSF samples in amyotrophic lateral sclerosis. Front Neurol. 2021;12: 663637.","journal-title":"Front Neurol"},{"key":"819_CR386","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13195-022-01091-8","volume":"14","author":"K Katisko","year":"2022","unstructured":"Katisko K, Huber N, Kokkola T, Hartikainen P, Kruger J, Heikkinen AL, Paananen V, Leinonen V, Korhonen VE, Helisalmi S, et al. Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype. Alzheimers Res Ther. 2022;14:151.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR387","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41591-023-02788-5","volume":"30","author":"KE Irwin","year":"2024","unstructured":"Irwin KE, Jasin P, Braunstein KE, Sinha IR, Garret MA, Bowden KD, Chang K, Troncoso JC, Moghekar A, Oh ES, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. Nat Med. 2024;30:382\u201393.","journal-title":"Nat Med"},{"key":"819_CR388","doi-asserted-by":"publisher","first-page":"eadg7162","DOI":"10.1126\/scitranslmed.adg7162","volume":"16","author":"S Seddighi","year":"2024","unstructured":"Seddighi S, Qi YA, Brown AL, Wilkins OG, Bereda C, Belair C, Zhang YJ, Prudencio M, Keuss MJ, Khandeshi A, et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS\/FTD. Sci Transl Med. 2024;16:eadg7162.","journal-title":"Sci Transl Med"},{"key":"819_CR389","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00401-024-02732-y","volume":"147","author":"I Costantino","year":"2024","unstructured":"Costantino I, Meng A, Ravits J. Alternatively spliced ELAVL3 cryptic exon 4a causes ELAVL3 downregulation in ALS TDP-43 proteinopathy. Acta Neuropathol. 2024;147:93.","journal-title":"Acta Neuropathol"},{"key":"819_CR390","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","volume":"30","author":"M Chatterjee","year":"2024","unstructured":"Chatterjee M, Ozdemir S, Fritz C, Mobius W, Kleineidam L, Mandelkow E, Biernat J, Dogdu C, Peters O, Cosma NC, et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat Med. 2024;30:1771\u201383.","journal-title":"Nat Med"},{"key":"819_CR391","doi-asserted-by":"publisher","first-page":"588","DOI":"10.20517\/evcna.2023.44","volume":"4","author":"V Hook","year":"2023","unstructured":"Hook V, Podvin S, Mosier C, Boyarko B, Seyffert L, Stringer H, Rissman RA. Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin. Extracell Vesicles Circ Nucl Acids. 2023;4:588\u201398.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"key":"819_CR392","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","volume":"17","author":"ME Murray","year":"2022","unstructured":"Murray ME, Moloney CM, Kouri N, Syrjanen JA, Matchett BJ, Rothberg DM, Tranovich JF, Sirmans TNH, Wiste HJ, Boon BDC, et al. Global neuropathologic severity of Alzheimer\u2019s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Mol Neurodegener. 2022;17:85.","journal-title":"Mol Neurodegener"},{"key":"819_CR393","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02570-4","volume":"146","author":"L Yu","year":"2023","unstructured":"Yu L, Boyle PA, Janelidze S, Petyuk VA, Wang T, Bennett DA, Hansson O, Schneider JA. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. 2023;146:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"819_CR394","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer\u2019s disease. Neuron. 2013;80:1347\u201358.","journal-title":"Neuron"},{"key":"819_CR395","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s40478-019-0837-9","volume":"7","author":"DR Thal","year":"2019","unstructured":"Thal DR, Ronisz A, Tousseyn T, Rijal Upadhaya A, Balakrishnan K, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Otto M, Beach TG, et al. Different aspects of Alzheimer\u2019s disease-related amyloid beta-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathol Commun. 2019;7:178.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR396","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23:191\u2013204.","journal-title":"Lancet Neurol"},{"key":"819_CR397","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23:178\u201390.","journal-title":"Lancet Neurol"},{"key":"819_CR398","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/mds.30028","volume":"39","author":"GG Kovacs","year":"2024","unstructured":"Kovacs GG, Grinberg LT, Halliday G, Alafuzoff I, Dugger BN, Murayama S, Forrest SL, Martinez-Valbuena I, Tanaka H, Kon T, et al. Biomarker-based approach to alpha-Synucleinopathies: lessons from neuropathology. Mov Disord. 2024;39:2173\u20139.","journal-title":"Mov Disord"},{"key":"819_CR399","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15 e11-14.","journal-title":"Alzheimers Dement"},{"key":"819_CR400","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/alz.13908","volume":"20","author":"A Leuzy","year":"2024","unstructured":"Leuzy A, Raket LL, Villemagne VL, Klein G, Tonietto M, Olafson E, Baker S, Saad ZS, Bullich S, Lopresti B, et al. Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: the CenTauR scale and the joint propagation model. Alzheimers Dement. 2024;20:5833\u201348.","journal-title":"Alzheimers Dement"},{"key":"819_CR401","doi-asserted-by":"publisher","DOI":"10.1002\/alz.077714","volume":"19","author":"PM Thompson","year":"2023","unstructured":"Thompson PM, Raj T. Artificial Intelligence and Machine Learning (AIML) approaches to empower genomics, drug, and biomarker discovery in ADRD. Alzheimers Dement. 2023;19: e077714.","journal-title":"Alzheimers Dement"},{"key":"819_CR402","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.1038\/s41598-024-58223-3","volume":"14","author":"Y Momota","year":"2024","unstructured":"Momota Y, Bun S, Hirano J, Kamiya K, Ueda R, Iwabuchi Y, Takahata K, Yamamoto Y, Tezuka T, Kubota M, et al. Amyloid-beta prediction machine learning model using source-based morphometry across neurocognitive disorders. Sci Rep. 2024;14:7633.","journal-title":"Sci Rep"},{"key":"819_CR403","doi-asserted-by":"publisher","DOI":"10.1177\/15333175241308645","volume":"39","author":"VK Tiwari","year":"2024","unstructured":"Tiwari VK, Indic P, Tabassum S. A study on machine learning models in detecting cognitive impairments in Alzheimer\u2019s patients using cerebrospinal fluid biomarkers. Am J Alzheimers Dis Other Demen. 2024;39: 15333175241308645.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"819_CR404","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jon.12214","volume":"25","author":"M Dyrba","year":"2015","unstructured":"Dyrba M, Barkhof F, Fellgiebel A, Filippi M, Hausner L, Hauenstein K, Kirste T, Teipel SJ, group Es. Predicting prodromal Alzheimer\u2019s disease in subjects with mild cognitive impairment using machine learning classification of multimodal multicenter diffusion-tensor and magnetic resonance imaging data. J Neuroimaging. 2015;25:738\u201347.","journal-title":"J Neuroimaging"},{"key":"819_CR405","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1109\/JBHI.2020.2984355","volume":"25","author":"CS Eke","year":"2021","unstructured":"Eke CS, Jammeh E, Li X, Carroll C, Pearson S, Ifeachor E. Early detection of Alzheimer\u2019s disease with blood plasma proteins using support vector machines. IEEE J Biomed Health Inform. 2021;25:218\u201326.","journal-title":"IEEE J Biomed Health Inform"},{"key":"819_CR406","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1093\/brain\/awac202","volume":"145","author":"X Li","year":"2022","unstructured":"Li X, Ospitalieri S, Robberechts T, Hofmann L, Schmid C, Rijal Upadhaya A, Koper MJ, von Arnim CAF, Kumar S, Willem M, et al. Seeding, maturation and propagation of amyloid beta-peptide aggregates in Alzheimer\u2019s disease. Brain. 2022;145:3558\u201370.","journal-title":"Brain"},{"key":"819_CR407","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00401-018-1855-6","volume":"136","author":"SK Kaufman","year":"2018","unstructured":"Kaufman SK, Del Tredici K, Thomas TL, Braak H, Diamond MI. Tau seeding activity begins in the transentorhinal\/entorhinal regions and anticipates phospho-tau pathology in Alzheimer\u2019s disease and PART. Acta Neuropathol. 2018;136:57\u201367.","journal-title":"Acta Neuropathol"},{"key":"819_CR408","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/nn.4117","volume":"18","author":"L Ye","year":"2015","unstructured":"Ye L, Fritschi SK, Schelle J, Obermuller U, Degenhardt K, Kaeser SA, Eisele YS, Walker LC, Baumann F, Staufenbiel M, Jucker M. Persistence of Abeta seeds in APP null mouse brain. Nat Neurosci. 2015;18:1559\u201361.","journal-title":"Nat Neurosci"},{"key":"819_CR409","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3233\/JAD-190264","volume":"71","author":"A Charil","year":"2019","unstructured":"Charil A, Shcherbinin S, Southekal S, Devous MD, Mintun M, Murray ME, Miller BB, Schwarz AJ. Tau subtypes of Alzheimer\u2019s disease determined in vivo using flortaucipir PET imaging. J Alzheimers Dis. 2019;71:1037\u201348.","journal-title":"J Alzheimers Dis"},{"key":"819_CR410","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40478-022-01471-z","volume":"10","author":"D Ferreira","year":"2022","unstructured":"Ferreira D, Mohanty R, Murray ME, Nordberg A, Kantarci K, Westman E. The hippocampal sparing subtype of Alzheimer\u2019s disease assessed in neuropathology and in vivo tau positron emission tomography: a systematic review. Acta Neuropathol Commun. 2022;10:166.","journal-title":"Acta Neuropathol Commun"},{"key":"819_CR411","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/s41467-018-05892-0","volume":"9","author":"AL Young","year":"2018","unstructured":"Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat Commun. 2018;9:4273.","journal-title":"Nat Commun"},{"key":"819_CR412","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/01.STR.14.6.915","volume":"14","author":"JJ Gilbert","year":"1983","unstructured":"Gilbert JJ, Vinters HV. Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage. Stroke. 1983;14:915\u201323.","journal-title":"Stroke"},{"key":"819_CR413","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-008-0366-2","volume":"115","author":"DR Thal","year":"2008","unstructured":"Thal DR, Griffin WST, De Vos RAI, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer\u2019s disease. Acta Neuropathol. 2008;115:599\u2013609.","journal-title":"Acta Neuropathol"},{"key":"819_CR414","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani RJ, Shanes ED, McCord M, Reish NJ, Flanagan ME, Mesulam MM, Jamshidi P. Neuropathology of anti-amyloid-beta immunotherapy: a case report. J Alzheimers Dis. 2023;93:803\u201313.","journal-title":"J Alzheimers Dis"},{"key":"819_CR415","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC. Alzheimer\u2019s disease: from immunotherapy to immunoprevention. Cell. 2023;186:4260\u201370.","journal-title":"Cell"},{"key":"819_CR416","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1126\/science.adi6515","volume":"380","author":"J Travis","year":"2023","unstructured":"Travis J. Latest Alzheimer\u2019s antibody is \u201cnot a miracle drug.\u201d Science. 2023;380:571.","journal-title":"Science"},{"key":"819_CR417","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1093\/brain\/awac181","volume":"145","author":"JC Morris","year":"2022","unstructured":"Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, et al. Autosomal dominant and sporadic late onset Alzheimer\u2019s disease share a common in vivo pathophysiology. Brain. 2022;145:3594\u2013607.","journal-title":"Brain"},{"key":"819_CR418","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"819_CR419","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","volume":"48","author":"BJ Hanseeuw","year":"2021","unstructured":"Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, Woodard JL, Buckley C, Farrar G, Ivanoiu A, Lhommel R. Defining a centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48:302\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"819_CR420","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, Hansson O. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13:68.","journal-title":"Alzheimers Res Ther"},{"key":"819_CR421","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cortex.2019.11.002","volume":"124","author":"RL Utianski","year":"2019","unstructured":"Utianski RL, Martin PR, Botha H, Schwarz CG, Duffy JR, Petersen RC, Knopman DS, Clark HM, Butts AM, Machulda MM, et al. Longitudinal flortaucipir ([(18)F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex. 2019;124:33\u201343.","journal-title":"Cortex"},{"issue":"1932\u20131943","key":"819_CR422","first-page":"e1935","volume":"110","author":"WJ Lee","year":"2022","unstructured":"Lee WJ, Brown JA, Kim HR, La Joie R, Cho H, Lyoo CH, Rabinovici GD, Seong JK, Seeley WW, Alzheimer\u2019s Disease Neuroimaging I. Regional Abeta-tau interactions promote onset and acceleration of Alzheimer\u2019s disease tau spreading. Neuron. 2022;110(1932\u20131943):e1935.","journal-title":"Neuron"},{"key":"819_CR423","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"819_CR424","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, Becker G, Seret A, Mella C, Giacomelli F, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47:390\u2013402.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"819_CR425","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, Chen MK, O\u2019Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimers Dement. 2020;16:974\u201382.","journal-title":"Alzheimers Dement"},{"key":"819_CR426","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2967\/jnumed.120.249144","volume":"62","author":"M Naganawa","year":"2021","unstructured":"Naganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, et al. First-in-human evaluation of (18)F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2021;62:561\u20137.","journal-title":"J Nucl Med"},{"key":"819_CR427","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1038\/s41380-022-01672-x","volume":"27","author":"G Vanderlinden","year":"2022","unstructured":"Vanderlinden G, Ceccarini J, Vande Casteele T, Michiels L, Lemmens R, Triau E, Serdons K, Tournoy J, Koole M, Vandenbulcke M, Van Laere K. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Mol Psychiatry. 2022;27:4244\u201351.","journal-title":"Mol Psychiatry"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00819-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:03:18Z","timestamp":1741935798000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00819-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":427,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00819-y","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases was granted by the ethical committee of Ulm University (Germany, study 54\/08) and UZ\/KU-Leuven ethical committee (Belgium). The studies reviewed here covering the retrospective analysis of samples and data were approved by the UZ\/KU-Leuven ethical committee (S-59295, S-65147, S-66705) (Belgium). The samples obtained from the UK were received from the brainbank donated for research by GE Healthcare after the phase III flutemetamol autopsy study had concluded (ClinicalTrials. gov identifiers NCT01165554, and NCT02090855).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this study, which did not use person\u2019s data. Only anonymized or pseudonymized data were processed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DRT collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), and GE-Healthcare (UK) and received consultant honoraria from Muna Therapeutics (Belgium). DRT is vice chair of the Alzheimer's Association ISTAART professional interest area \u201cThe eye as a biomarker for AD\u201d. RV\u2019s institution has clinical trial agreements (RV as PI) with Alector, AviadoBio, Biogen, Denali, J&J, Eli Lilly and UCB. RV\u2019s institution has consultancy agreements (RV as member of DSMB) with AC Immune. RV was global PI of the industry-sponsored pivotal phase 2 flutemetamol trial. KP has a consultancy agreement with Eisai. KP\u2019s institution has biomarker trial agreements with ADx NeuroSciences, Euroimmun and Fujirebio. KP is member of the scientific advisory board of Stichting Alzheimer Onderzoek\/Fondation Recherche Alzheimer, Belgium. SDM reported no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}